[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f_j90YgNfq3UuIzZFxMVnr9sFVTr6zsyti5BQM7Ojd_s":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":84,"rows":91},"Centre Hospitalier Universitaire, Amiens",[4],568,false,170,47,415557,64,445,[14,17,19,22,24,27,29,31],{"name":15,"count":16},"Covid19",10,{"name":18,"count":16},"Septic Shock",{"name":20,"count":21},"Surgery",9,{"name":23,"count":21},"Stroke",{"name":25,"count":26},"Thoracic Surgery",8,{"name":28,"count":26},"Alzheimer Disease",{"name":30,"count":26},"Cardiac Surgery",{"name":32,"count":33},"Acute Kidney Injury",7,[35,40,45,50,55,60,65,70,75,79],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03927079","Predictive Factors of Good Pulmonary Penetration of Antibiotics : AntiBiotics Dosage in Broncho-Alveolar Lavage","2022-04-01","measure of intra-alveolar antibiotic concentration in µg\u002Fml",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04469491","Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study","2023-06-16","inhaled type I interferon",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT04741464","Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis","2023-11-22","Tinzaparin",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT03580733","Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis","2024-10-04","caspofungin antifungal therapy",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT03935139","Monitoring of the Bone Free Flaps With Microdialysis","2024-12","glucose measurement",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07264504","Experimentation of Formaldehyde Purification by Plants in the Anatomy and Cytology Department","2024-12-31","Biological measurement of urinary formic acid",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06853340","Impact of Vascular Calcification and CASR Expression by Monocytes in Septic Shock","2025-04-01","blood sampling",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05515809","Evaluation of the Effect of Para-sternal Block on Postoperative Respiratory Function After Cardiac Sternotomy Surgery","2025-06","parasternal block",{"nctId":76,"briefTitle":77,"date":73,"intervention":78},"NCT05922982","Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery","norepinephrine weaning protocol",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06502457","Pain Management With Virtual Reality Hypnosis","2025-07","painkiller",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,149,354,397,437,495,513,531,561,579,597,615,639,666,684,709,733,751,777,795,813,831,853,879,902,928,946,972,995,1013,1071,1118,1164,1199,1217,1241,1259,1277,1295,1331,1349,1367,1385,1403,1432,1450,1475,1493,1511,1537,1558,1587,1605,1631,1655,1678,1704,1727,1745,1769,1791,1809,1831,1858,1884,1902,1927,1945,1970,1988,2013,2031,2059,2096,2120,2147,2165,2183,2209,2227,2254,2279,2304,2330,2348,2374,2399,2424,2448,2473,2498,2524,2550,2568,2594,2618,2636,2660,2684,2710,2738,2756,2774,2800,2825,2843,2886,2910,2935,2959,2981,3006,3024,3051,3069,3095,3120,3144,3171,3205,3223,3241,3265,3289,3313,3339,3362,3388,3412,3437,3461,3487,3505,3534,3552,3577,3602],{"intervention":93,"totalTrials":94,"cells":95},"blood test",3,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":135},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":134,"soonestReadout":125},[107,120],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":119},"NCT03926377","Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid","UNKNOWN",[89],"2023-10","2024-04","2019-04-01",50,[117,118],"Osteoporosis","Bullous Pemphigoid",[93],{"nctId":121,"briefTitle":122,"status":123,"phases":124,"primaryCompletion":125,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":133},"NCT06634641","Clozapine-related Immunodeficiency in Parkinsons Disease","RECRUITING",[89],"2027-09","2024-10-01",24,[129,130,131,132],"Clozapine","Parkinson's Disease (PD)","Immunodeficiency","Psychosis",[93],1,{"trials":136,"activeCount":134,"soonestReadout":142},[137],{"nctId":138,"briefTitle":139,"status":140,"phases":141,"primaryCompletion":142,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":148},"NCT04563676","Physiopathology and Sequelae of COVID-19 Infection","ACTIVE_NOT_RECRUITING",[90],"2025-12","2020-09-22",400,[15,146,147],"TSH","Cortisol",[93],{"intervention":150,"totalTrials":151,"cells":152},"blood sample",15,{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":176,"NA":178},{"trials":154,"activeCount":98},[],{"trials":156,"activeCount":98},[],{"trials":158,"activeCount":98},[],{"trials":160,"activeCount":134,"soonestReadout":165},[161],{"nctId":162,"briefTitle":163,"status":123,"phases":164,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":173},"NCT05040464","Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial",[88],"2026-08","2027-05","2021-08-26",166,[170,171,172],"Crohn Disease","Azathioprine","Methotrexate",[174,175,150],"AZA","MTX",{"trials":177,"activeCount":98},[],{"trials":179,"activeCount":21,"soonestReadout":310},[180,196,207,218,229,242,255,268,281,294,306,315,325,342],{"nctId":181,"briefTitle":182,"status":123,"phases":183,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":194},"NCT07464600","CRP Point-of-care Testing Trajectory, a Predictive Factor for Anastomotic Leak in Elective Colorectal Surgery",[90],"2028-11","2029-02","2025-09-17",500,[189,190,191,192,193],"Colorectal Surgery","Enhanced Recovery","CRP Point-of-care Testing Trajectory","Post-operative Complication","Anastomotic Leak",[150,195],"Blood taken from a fingertip",{"nctId":197,"briefTitle":198,"status":110,"phases":199,"primaryCompletion":200,"completion":200,"start":201,"enrollment":202,"conditions":203,"interventions":206},"NCT04938479","D-dimer Prognostic Marker of Cerebral Infarction After Revascularization Procedure",[],"2023-09","2021-06-15",60,[204,205],"Cerebral Infarction","Cerebral Infarction Recovery",[150],{"nctId":208,"briefTitle":209,"status":123,"phases":210,"primaryCompletion":211,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":217},"NCT04711746","Is Clonal Hematopoiesis of Indeterminate Potential Associated With Unprovoked Pulmonary Embolism?",[90],"2026-01","2021-02-01",544,[215,216],"Pulmonary Embolism","Hematopoiesis",[150],{"nctId":219,"briefTitle":220,"status":221,"phases":222,"primaryCompletion":223,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":228},"NCT02803645","Clinical Significance of Antiphospholipid Antibodies in Healthy Subjects","COMPLETED",[90],"2016-03","2007-07",1282,[227],"Antiphospholipid Antibodies",[150],{"nctId":230,"briefTitle":231,"status":110,"phases":232,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":241},"NCT04563650","COVID-19 Serology and Immunosenescence",[90],"2021-05-01","2024-11","2020-09-18",98,[15,238,239,240],"Geriatric Medicine","Seroconversion","Immunosenescence",[150],{"nctId":243,"briefTitle":244,"status":123,"phases":245,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":254},"NCT04377490","Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy",[],"2025-10","2025-11","2020-05-04",100,[251,252,253],"COVID-19","Hemostasis","Coagulation",[150],{"nctId":256,"briefTitle":257,"status":123,"phases":258,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":266},"NCT04893564","Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia",[90],"2027-07","2028-07","2022-05-16",90,[264,265],"Waldenstrom's Disease","Waldenstrom Macroglobulinemia",[267,150],"bone marrow sample",{"nctId":269,"briefTitle":270,"status":123,"phases":271,"primaryCompletion":272,"completion":166,"start":273,"enrollment":274,"conditions":275,"interventions":280},"NCT07203833","Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock",[90],"2027-04","2025-10-19",144,[276,18,277,278,279],"Vasorin","Shock","Biomarker","Infection",[150],{"nctId":282,"briefTitle":283,"status":123,"phases":284,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":292},"NCT06892171","The Study of the Phenotype of Hereditary Xerocytosis",[90],"2028-03","2025-03-01",20,[289,290,291],"Xerocytosis","Phenotype","Genotype",[293],"Blood sample",{"nctId":295,"briefTitle":296,"status":110,"phases":297,"primaryCompletion":298,"completion":58,"start":299,"enrollment":300,"conditions":301,"interventions":305},"NCT05648136","Immune Profile Analysis and Biomarker Identification in Women With Repeated Implantation Failure or Unexplained Recurrent Spontaneous Miscarriage",[90],"2024-05","2022-12-02",150,[302,303,304],"Repeated Embryo Implantation Failure","Recurrent Miscarriage","Immune System",[150],{"nctId":307,"briefTitle":308,"status":123,"phases":309,"primaryCompletion":310,"completion":165,"start":311,"enrollment":249,"conditions":312,"interventions":314},"NCT04898647","Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia",[90],"2025-08","2021-05-14",[313,265],"Hyperviscosity Syndrome",[150],{"nctId":316,"briefTitle":317,"status":123,"phases":318,"primaryCompletion":165,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":324},"NCT06555120","Screening for Familial Hypercholesterolemia in Children",[90],"2027-02","2025-01-02",300,[323],"Hypercholesterolemia, Familial",[150],{"nctId":326,"briefTitle":327,"status":123,"phases":328,"primaryCompletion":329,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":341},"NCT06033300","Characterization and Quantification of Platelet\u002FLeukocyte Aggregates in Patients With Suspected Heparin-induced Thrombocytopenia",[90],"2026-04","2023-04-17",200,[333,334,335,336,337,338,339,340],"Heparin-induced Thrombocytopenia","HIT","Platelet Activation","Platelets","Leukocytes","Platelet\u002FLeukocyte Aggregates","HITSTREAM","Flow Cytometry",[150],{"nctId":343,"briefTitle":344,"status":221,"phases":345,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":353},"NCT05815134","Cell Free DNA Quantification in Patients With Endometriosis Followed Witd Medical Assistance to Procreation",[90],"2023-07-01","2025-07-01","2020-08-26",114,[351,352],"Endometriosis","Cell Free DNA",[150],{"intervention":355,"totalTrials":356,"cells":357},"ketoprofen",2,{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":378,"PHASE4":393,"NA":395},{"trials":359,"activeCount":98},[],{"trials":361,"activeCount":98},[],{"trials":363,"activeCount":134,"soonestReadout":368},[364],{"nctId":365,"briefTitle":366,"status":123,"phases":367,"primaryCompletion":368,"completion":184,"start":369,"enrollment":370,"conditions":371,"interventions":376},"NCT06731647","Non-steroidal Anti-inflammatory Drugs in Pleurodesis",[87],"2027-11","2025-02-01",358,[372,373,374,375],"Non-steroidal Anti-inflammatory Drugs","Pleurodesis","Pneumothorax","Pain Management",[377],"KETOPROFEN",{"trials":379,"activeCount":134,"soonestReadout":384},[380],{"nctId":381,"briefTitle":382,"status":123,"phases":383,"primaryCompletion":384,"completion":259,"start":385,"enrollment":386,"conditions":387,"interventions":391},"NCT06381063","Non-steroidal Anti-inflammatory in Cardiac Surgery",[88],"2027-03","2024-03-27",238,[388,372,30,389,390],"Acute Postoperative Pain","Pain Intensity","Multimodal Pain Management",[392,355],"pain management",{"trials":394,"activeCount":98},[],{"trials":396,"activeCount":98},[],{"intervention":398,"totalTrials":356,"cells":399},"Antibiotics",{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":406,"PHASE4":419,"NA":421},{"trials":401,"activeCount":98},[],{"trials":403,"activeCount":98},[],{"trials":405,"activeCount":98},[],{"trials":407,"activeCount":134,"soonestReadout":412},[408],{"nctId":409,"briefTitle":410,"status":123,"phases":411,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":418},"NCT03688295","The Value of Post-operative Antibiotic Therapy After Laparoscopic Appendectomy for Complicated Acute Appendicitis (Other Than for Generalized Peritonitis)",[88],"2025-09-01","2026-09-01","2019-02-01",1476,[417],"Complicated Acute Appendicitis",[398],{"trials":420,"activeCount":98},[],{"trials":422,"activeCount":134,"soonestReadout":384},[423],{"nctId":424,"briefTitle":425,"status":123,"phases":426,"primaryCompletion":384,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":435},"NCT07030673","Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection",[90],"2027-06","2025-02-14",256,[431,432,433,434],"Elderly","Antibiotics Overuse","Viral Infections","PCR Multiplex",[436,398],"antibiotic withdrawal",{"intervention":438,"totalTrials":94,"cells":439},"ropivacaine",{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":465,"NA":493},{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":98},[],{"trials":445,"activeCount":98},[],{"trials":447,"activeCount":134,"soonestReadout":453},[448],{"nctId":449,"briefTitle":450,"status":451,"phases":452,"primaryCompletion":453,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":462},"NCT07414706","Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery","NOT_YET_RECRUITING",[88],"2028-06","2028-09","2026-03",182,[458,459,460,461],"Intravenous Lidocaine","Laparoscopic Surgery","Post Operative Recovery","Local Anaesthetic Systemic Toxicity",[463,438,464],"Procedure\u002FStandard care","Lidocaine",{"trials":466,"activeCount":98},[467,478],{"nctId":468,"briefTitle":469,"status":221,"phases":470,"primaryCompletion":471,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":476},"NCT00567450","Ropivacaine Versus Ropivacaine Plus Mepivacaine for Sciatic Block",[89],"2008-09","2007-09",30,[475],"Subgluteal Sciatic Block",[438,477],"ropivacaine plus mepivacaine",{"nctId":479,"briefTitle":480,"status":221,"phases":481,"primaryCompletion":482,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":491},"NCT05368753","Evaluation of Plasma Concentrations of Intravenous Lidocaine and Epidural Ropivacaine When Used in Combination in Major Abdominal Surgery",[89],"2024-01-28","2024-10-02","2022-03-09",51,[487,488,489,490],"Abdominal Surgery by Laparotomy","Thoracic Epidural Analgesia","Analgesia","Lidocaine Adverse Reaction",[492,438],"Lidocain",{"trials":494,"activeCount":98},[],{"intervention":463,"totalTrials":134,"cells":496},{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":501,"PHASE3":503,"PHASE4":509,"NA":511},{"trials":498,"activeCount":98},[],{"trials":500,"activeCount":98},[],{"trials":502,"activeCount":98},[],{"trials":504,"activeCount":134,"soonestReadout":453},[505],{"nctId":449,"briefTitle":450,"status":451,"phases":506,"primaryCompletion":453,"completion":454,"start":455,"enrollment":456,"conditions":507,"interventions":508},[88],[458,459,460,461],[463,438,464],{"trials":510,"activeCount":98},[],{"trials":512,"activeCount":98},[],{"intervention":464,"totalTrials":134,"cells":514},{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":527,"NA":529},{"trials":516,"activeCount":98},[],{"trials":518,"activeCount":98},[],{"trials":520,"activeCount":98},[],{"trials":522,"activeCount":134,"soonestReadout":453},[523],{"nctId":449,"briefTitle":450,"status":451,"phases":524,"primaryCompletion":453,"completion":454,"start":455,"enrollment":456,"conditions":525,"interventions":526},[88],[458,459,460,461],[463,438,464],{"trials":528,"activeCount":98},[],{"trials":530,"activeCount":98},[],{"intervention":532,"totalTrials":134,"cells":533},"Clarithromycin 1000 MG",{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":557,"NA":559},{"trials":535,"activeCount":98},[],{"trials":537,"activeCount":98},[],{"trials":539,"activeCount":98},[],{"trials":541,"activeCount":134,"soonestReadout":546},[542],{"nctId":543,"briefTitle":544,"status":123,"phases":545,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":550,"interventions":553},"NCT03236987","CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections",[88],"2028-02-05","2029-02-05","2018-02-05",424,[551,552],"Lung Infection","MAC Lung Disease",[532,554,555,556],"Azithromycin 250 mg","Rifampicin","Ethambutol",{"trials":558,"activeCount":98},[],{"trials":560,"activeCount":98},[],{"intervention":554,"totalTrials":134,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":569,"PHASE4":575,"NA":577},{"trials":564,"activeCount":98},[],{"trials":566,"activeCount":98},[],{"trials":568,"activeCount":98},[],{"trials":570,"activeCount":134,"soonestReadout":546},[571],{"nctId":543,"briefTitle":544,"status":123,"phases":572,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":573,"interventions":574},[88],[551,552],[532,554,555,556],{"trials":576,"activeCount":98},[],{"trials":578,"activeCount":98},[],{"intervention":555,"totalTrials":134,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":593,"NA":595},{"trials":582,"activeCount":98},[],{"trials":584,"activeCount":98},[],{"trials":586,"activeCount":98},[],{"trials":588,"activeCount":134,"soonestReadout":546},[589],{"nctId":543,"briefTitle":544,"status":123,"phases":590,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":591,"interventions":592},[88],[551,552],[532,554,555,556],{"trials":594,"activeCount":98},[],{"trials":596,"activeCount":98},[],{"intervention":556,"totalTrials":134,"cells":598},{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":611,"NA":613},{"trials":600,"activeCount":98},[],{"trials":602,"activeCount":98},[],{"trials":604,"activeCount":98},[],{"trials":606,"activeCount":134,"soonestReadout":546},[607],{"nctId":543,"briefTitle":544,"status":123,"phases":608,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":609,"interventions":610},[88],[551,552],[532,554,555,556],{"trials":612,"activeCount":98},[],{"trials":614,"activeCount":98},[],{"intervention":616,"totalTrials":134,"cells":617},"hydrocortisone plus fludrocortisone",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":635,"NA":637},{"trials":619,"activeCount":98},[],{"trials":621,"activeCount":98},[],{"trials":623,"activeCount":98},[],{"trials":625,"activeCount":134,"soonestReadout":630},[626],{"nctId":627,"briefTitle":628,"status":451,"phases":629,"primaryCompletion":630,"completion":453,"start":310,"enrollment":631,"conditions":632,"interventions":634},"NCT07037043","Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing for Cardiac Surgery",[88],"2028-05",196,[633],"Inflammation in Cardiac Surgery",[616],{"trials":636,"activeCount":98},[],{"trials":638,"activeCount":98},[],{"intervention":640,"totalTrials":134,"cells":641},"noradrenaline and vascular filling",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":662,"NA":664},{"trials":643,"activeCount":98},[],{"trials":645,"activeCount":98},[],{"trials":647,"activeCount":98},[],{"trials":649,"activeCount":134,"soonestReadout":259},[650],{"nctId":651,"briefTitle":652,"status":123,"phases":653,"primaryCompletion":259,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":661},"NCT05481723","Lung Ultrasound-guided Hemodynamic Optimization",[88],"2027-08","2022-07-28",350,[658,659,660],"Lung Ultrasound","Goal Directed Therapy","Non-cardiac Surgery",[640],{"trials":663,"activeCount":98},[],{"trials":665,"activeCount":98},[],{"intervention":392,"totalTrials":134,"cells":667},{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":674,"PHASE4":680,"NA":682},{"trials":669,"activeCount":98},[],{"trials":671,"activeCount":98},[],{"trials":673,"activeCount":98},[],{"trials":675,"activeCount":134,"soonestReadout":384},[676],{"nctId":381,"briefTitle":382,"status":123,"phases":677,"primaryCompletion":384,"completion":259,"start":385,"enrollment":386,"conditions":678,"interventions":679},[88],[388,372,30,389,390],[392,355],{"trials":681,"activeCount":98},[],{"trials":683,"activeCount":98},[],{"intervention":685,"totalTrials":134,"cells":686},"Landiolol",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":705,"NA":707},{"trials":688,"activeCount":98},[],{"trials":690,"activeCount":98},[],{"trials":692,"activeCount":98},[],{"trials":694,"activeCount":134,"soonestReadout":427},[695],{"nctId":696,"briefTitle":697,"status":123,"phases":698,"primaryCompletion":427,"completion":125,"start":212,"enrollment":699,"conditions":700,"interventions":704},"NCT04748796","Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility",[88],360,[18,701,702,703],"Tachycardia","Mortality During Septic Shock","Beta-blocker",[685],{"trials":706,"activeCount":98},[],{"trials":708,"activeCount":98},[],{"intervention":74,"totalTrials":134,"cells":710},{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":717,"PHASE4":729,"NA":731},{"trials":712,"activeCount":98},[],{"trials":714,"activeCount":98},[],{"trials":716,"activeCount":98},[],{"trials":718,"activeCount":134,"soonestReadout":73},[719],{"nctId":71,"briefTitle":72,"status":140,"phases":720,"primaryCompletion":73,"completion":73,"start":721,"enrollment":722,"conditions":723,"interventions":727},[88],"2022-07-19",84,[30,724,725,726],"Ultrasound-guided Parasternal Block","Postoperative Pulmonary Complications","Pulmonary Function Testing",[74,728],"Standard pain management",{"trials":730,"activeCount":98},[],{"trials":732,"activeCount":98},[],{"intervention":728,"totalTrials":134,"cells":734},{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":741,"PHASE4":747,"NA":749},{"trials":736,"activeCount":98},[],{"trials":738,"activeCount":98},[],{"trials":740,"activeCount":98},[],{"trials":742,"activeCount":134,"soonestReadout":73},[743],{"nctId":71,"briefTitle":72,"status":140,"phases":744,"primaryCompletion":73,"completion":73,"start":721,"enrollment":722,"conditions":745,"interventions":746},[88],[30,724,725,726],[74,728],{"trials":748,"activeCount":98},[],{"trials":750,"activeCount":98},[],{"intervention":752,"totalTrials":134,"cells":753},"lidocaine treatment",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":760,"PHASE4":773,"NA":775},{"trials":755,"activeCount":98},[],{"trials":757,"activeCount":98},[],{"trials":759,"activeCount":98},[],{"trials":761,"activeCount":134,"soonestReadout":766},[762],{"nctId":763,"briefTitle":764,"status":123,"phases":765,"primaryCompletion":766,"completion":766,"start":767,"enrollment":768,"conditions":769,"interventions":771},"NCT03984656","Evaluation of the Analgesia by Serratus Plane Block During Pleural Drainage in Intensive Care Unit.",[88],"2026-09-06","2019-06-04",70,[489,464,770],"Intensive Care Unit",[752,772],"serratus plane block treatment",{"trials":774,"activeCount":98},[],{"trials":776,"activeCount":98},[],{"intervention":772,"totalTrials":134,"cells":778},{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":785,"PHASE4":791,"NA":793},{"trials":780,"activeCount":98},[],{"trials":782,"activeCount":98},[],{"trials":784,"activeCount":98},[],{"trials":786,"activeCount":134,"soonestReadout":766},[787],{"nctId":763,"briefTitle":764,"status":123,"phases":788,"primaryCompletion":766,"completion":766,"start":767,"enrollment":768,"conditions":789,"interventions":790},[88],[489,464,770],[752,772],{"trials":792,"activeCount":98},[],{"trials":794,"activeCount":98},[],{"intervention":174,"totalTrials":134,"cells":796},{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":803,"PHASE4":809,"NA":811},{"trials":798,"activeCount":98},[],{"trials":800,"activeCount":98},[],{"trials":802,"activeCount":98},[],{"trials":804,"activeCount":134,"soonestReadout":165},[805],{"nctId":162,"briefTitle":163,"status":123,"phases":806,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":807,"interventions":808},[88],[170,171,172],[174,175,150],{"trials":810,"activeCount":98},[],{"trials":812,"activeCount":98},[],{"intervention":175,"totalTrials":134,"cells":814},{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":821,"PHASE4":827,"NA":829},{"trials":816,"activeCount":98},[],{"trials":818,"activeCount":98},[],{"trials":820,"activeCount":98},[],{"trials":822,"activeCount":134,"soonestReadout":165},[823],{"nctId":162,"briefTitle":163,"status":123,"phases":824,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":825,"interventions":826},[88],[170,171,172],[174,175,150],{"trials":828,"activeCount":98},[],{"trials":830,"activeCount":98},[],{"intervention":54,"totalTrials":134,"cells":832},{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":839,"PHASE4":849,"NA":851},{"trials":834,"activeCount":98},[],{"trials":836,"activeCount":98},[],{"trials":838,"activeCount":98},[],{"trials":840,"activeCount":134,"soonestReadout":53},[841],{"nctId":51,"briefTitle":52,"status":123,"phases":842,"primaryCompletion":53,"completion":843,"start":844,"enrollment":845,"conditions":846,"interventions":848},[88],"2024-12-04","2019-01-01",448,[847],"ICU Yeast Intra-abdominal Infection",[54],{"trials":850,"activeCount":98},[],{"trials":852,"activeCount":98},[],{"intervention":854,"totalTrials":134,"cells":855},"Nicotinamide treatment",{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":862,"PHASE4":875,"NA":877},{"trials":857,"activeCount":98},[],{"trials":859,"activeCount":98},[],{"trials":861,"activeCount":98},[],{"trials":863,"activeCount":134,"soonestReadout":868},[864],{"nctId":865,"briefTitle":866,"status":140,"phases":867,"primaryCompletion":868,"completion":868,"start":869,"enrollment":870,"conditions":871,"interventions":874},"NCT04589546","Does High-dose Vitamin B3 Supplementation Prevent Major Adverse Kidney Events During Septic Shock?",[88],"2025-09","2020-10-01",310,[32,18,872,873],"Nicotinamide","Mortality",[854],{"trials":876,"activeCount":98},[],{"trials":878,"activeCount":98},[],{"intervention":880,"totalTrials":134,"cells":881},"Sirolimus",{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":883,"activeCount":98},[],{"trials":885,"activeCount":98},[],{"trials":887,"activeCount":134,"soonestReadout":125},[888],{"nctId":889,"briefTitle":890,"status":123,"phases":891,"primaryCompletion":125,"completion":125,"start":892,"enrollment":115,"conditions":893,"interventions":895},"NCT02042326","Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations",[87],"2014-09-12",[894],"Arteriovenous Malformations",[880],{"trials":897,"activeCount":98},[],{"trials":899,"activeCount":98},[],{"trials":901,"activeCount":98},[],{"intervention":903,"totalTrials":134,"cells":904},"Arikayce",{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":922,"PHASE4":924,"NA":926},{"trials":906,"activeCount":98},[],{"trials":908,"activeCount":98},[],{"trials":910,"activeCount":134,"soonestReadout":165},[911],{"nctId":912,"briefTitle":913,"status":123,"phases":914,"primaryCompletion":165,"completion":654,"start":915,"enrollment":916,"conditions":917,"interventions":920},"NCT06585020","Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection",[87],"2024-10-20",190,[918,919],"Mycobacterium; Xenopi","Lung Diseases",[903,921],"standard treatment",{"trials":923,"activeCount":98},[],{"trials":925,"activeCount":98},[],{"trials":927,"activeCount":98},[],{"intervention":921,"totalTrials":134,"cells":929},{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":940,"PHASE4":942,"NA":944},{"trials":931,"activeCount":98},[],{"trials":933,"activeCount":98},[],{"trials":935,"activeCount":134,"soonestReadout":165},[936],{"nctId":912,"briefTitle":913,"status":123,"phases":937,"primaryCompletion":165,"completion":654,"start":915,"enrollment":916,"conditions":938,"interventions":939},[87],[918,919],[903,921],{"trials":941,"activeCount":98},[],{"trials":943,"activeCount":98},[],{"trials":945,"activeCount":98},[],{"intervention":947,"totalTrials":134,"cells":948},"GCP intratumoral catheter",{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":966,"PHASE4":968,"NA":970},{"trials":950,"activeCount":98},[],{"trials":952,"activeCount":98},[],{"trials":954,"activeCount":134,"soonestReadout":329},[955],{"nctId":956,"briefTitle":957,"status":451,"phases":958,"primaryCompletion":329,"completion":272,"start":247,"enrollment":959,"conditions":960,"interventions":965},"NCT05835804","Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers",[87],39,[961,962,963,964],"Squamous Cell Carcinoma of the Head and Neck","Paclitaxel","Carboplatin","Nivolumab",[947],{"trials":967,"activeCount":98},[],{"trials":969,"activeCount":98},[],{"trials":971,"activeCount":98},[],{"intervention":44,"totalTrials":134,"cells":973},{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":978,"PHASE3":989,"PHASE4":991,"NA":993},{"trials":975,"activeCount":98},[],{"trials":977,"activeCount":98},[],{"trials":979,"activeCount":134,"soonestReadout":43},[980],{"nctId":41,"briefTitle":42,"status":140,"phases":981,"primaryCompletion":43,"completion":142,"start":982,"enrollment":983,"conditions":984,"interventions":987},[87],"2020-09-20",74,[251,985,986],"INTERFERON","NEBULIZATION",[44,988],"WFI water nebulization",{"trials":990,"activeCount":98},[],{"trials":992,"activeCount":98},[],{"trials":994,"activeCount":98},[],{"intervention":988,"totalTrials":134,"cells":996},{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1007,"PHASE4":1009,"NA":1011},{"trials":998,"activeCount":98},[],{"trials":1000,"activeCount":98},[],{"trials":1002,"activeCount":134,"soonestReadout":43},[1003],{"nctId":41,"briefTitle":42,"status":140,"phases":1004,"primaryCompletion":43,"completion":142,"start":982,"enrollment":983,"conditions":1005,"interventions":1006},[87],[251,985,986],[44,988],{"trials":1008,"activeCount":98},[],{"trials":1010,"activeCount":98},[],{"trials":1012,"activeCount":98},[],{"intervention":1014,"totalTrials":1015,"cells":1016},"blood withdrawal",4,{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1023,"PHASE4":1025,"NA":1027},{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":98},[],{"trials":1022,"activeCount":98},[],{"trials":1024,"activeCount":98},[],{"trials":1026,"activeCount":98},[],{"trials":1028,"activeCount":94,"soonestReadout":455},[1029,1040,1051,1059],{"nctId":1030,"briefTitle":1031,"status":123,"phases":1032,"primaryCompletion":272,"completion":272,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1039},"NCT06880107","Genetic Variants of Annexin A2 and Cryptogenic Stroke",[90],"2025-04-08",240,[1036,23,1037,1038],"Annexin A2","Genetic Variants of Host","Fibrinolysis",[1014],{"nctId":1041,"briefTitle":1042,"status":123,"phases":1043,"primaryCompletion":272,"completion":272,"start":1044,"enrollment":1045,"conditions":1046,"interventions":1050},"NCT06880094","Study of Congenital Orofacial Clefts by Implementing Optical Genome Mapping",[90],"2025-02-18",26,[1047,1048,1049],"Orofacial Clefts","Next Generation Sequencing (NGS)","Optical Genome Mapping",[1014],{"nctId":1052,"briefTitle":1053,"status":123,"phases":1054,"primaryCompletion":455,"completion":455,"start":1055,"enrollment":202,"conditions":1056,"interventions":1058},"NCT06373926","Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome",[90],"2025-02-05",[1057],"Antiphospholipid Syndrome",[1014],{"nctId":1060,"briefTitle":1061,"status":110,"phases":1062,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1069},"NCT04807231","Comparison Between Calculated Bioavailable Testosterone Level With Radio-immunoassay Result.",[],"2024-03","2021-03-11",270,[1067,1068],"Testosterone","Androgens",[1070],"Blood withdrawal",{"intervention":1072,"totalTrials":94,"cells":1073},"blood samples",{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1080,"PHASE4":1082,"NA":1084},{"trials":1075,"activeCount":98},[],{"trials":1077,"activeCount":98},[],{"trials":1079,"activeCount":98},[],{"trials":1081,"activeCount":98},[],{"trials":1083,"activeCount":98},[],{"trials":1085,"activeCount":134,"soonestReadout":272},[1086,1097,1108],{"nctId":1087,"briefTitle":1088,"status":221,"phases":1089,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":1092,"conditions":1093,"interventions":1095},"NCT02800954","Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma",[90],"2018-07-10","2009-02-23",111,[1094],"Multiple Myeloma",[1072,1096],"Bone marow samples",{"nctId":1098,"briefTitle":1099,"status":451,"phases":1100,"primaryCompletion":272,"completion":1101,"start":142,"enrollment":473,"conditions":1102,"interventions":1107},"NCT07211841","Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM)",[90],"2029-04",[1103,1104,1105,1106],"Glioblastoma","MRI Spectroscopy","Tumor Microenvironment","Biomarkers \u002F Blood",[1072],{"nctId":1109,"briefTitle":1110,"status":1111,"phases":1112,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":98,"conditions":1115,"interventions":1117},"NCT02815501","Thyroid Dysfunction and Obstetric Complications","WITHDRAWN",[],"2017-10-26","2012-03-01",[1116],"Pregnancy",[1072],{"intervention":69,"totalTrials":94,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1130},{"trials":1121,"activeCount":98},[],{"trials":1123,"activeCount":98},[],{"trials":1125,"activeCount":98},[],{"trials":1127,"activeCount":98},[],{"trials":1129,"activeCount":98},[],{"trials":1131,"activeCount":134,"soonestReadout":68},[1132,1142,1154],{"nctId":66,"briefTitle":67,"status":123,"phases":1133,"primaryCompletion":68,"completion":319,"start":1134,"enrollment":1135,"conditions":1136,"interventions":1141},[90],"2025-02-24",66,[18,1137,1138,1139,1140],"Calcium Sensing Receptor","Calcium Phosphate Disorders","Inflammation","Monocyte",[69],{"nctId":1143,"briefTitle":1144,"status":221,"phases":1145,"primaryCompletion":1146,"completion":1147,"start":1148,"enrollment":473,"conditions":1149,"interventions":1153},"NCT05885568","Validation of the Transport of Biological Material by Drone",[90],"2025-06-05","2025-10-01","2023-05-01",[1150,1151,1152],"Drone Transport","Biological Samples","Unmanned Aerial System",[69],{"nctId":1155,"briefTitle":1156,"status":221,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":115,"conditions":1160,"interventions":1162},"NCT06072508","Prognostic Interest of Vasorin in Septic Shock",[90],"2025-03-29","2023-07-03",[1161,32],"Sepsis",[1163],"Blood sampling",{"intervention":1165,"totalTrials":356,"cells":1166},"blood",{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1173,"PHASE4":1175,"NA":1177},{"trials":1168,"activeCount":98},[],{"trials":1170,"activeCount":98},[],{"trials":1172,"activeCount":98},[],{"trials":1174,"activeCount":98},[],{"trials":1176,"activeCount":98},[],{"trials":1178,"activeCount":134,"soonestReadout":1193},[1179,1189],{"nctId":1180,"briefTitle":1181,"status":221,"phases":1182,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":1185,"conditions":1186,"interventions":1188},"NCT02894047","Study of the Influence of the Expression of the Calcium-sensitive Receptor (CaSR) by Monocytes in the Synovial Liquid on Structural Alterations in Patients Diagnosed With Rheumatoid Arthritis in the Previous Two Years",[],"2015-10","2013-07",42,[1187],"Arthritis, Rheumatoid",[1165],{"nctId":1190,"briefTitle":1191,"status":123,"phases":1192,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":1195,"conditions":1196,"interventions":1197},"NCT02811653","Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease",[90],"2028-12-16","2015-12-16",155,[28],[1198],"Blood",{"intervention":195,"totalTrials":134,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1207,"PHASE4":1209,"NA":1211},{"trials":1202,"activeCount":98},[],{"trials":1204,"activeCount":98},[],{"trials":1206,"activeCount":98},[],{"trials":1208,"activeCount":98},[],{"trials":1210,"activeCount":98},[],{"trials":1212,"activeCount":134,"soonestReadout":184},[1213],{"nctId":181,"briefTitle":182,"status":123,"phases":1214,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":1215,"interventions":1216},[90],[189,190,191,192,193],[150,195],{"intervention":59,"totalTrials":134,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1227,"NA":1229},{"trials":1220,"activeCount":98},[],{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[],{"trials":1226,"activeCount":98},[],{"trials":1228,"activeCount":98},[],{"trials":1230,"activeCount":134,"soonestReadout":58},[1231],{"nctId":56,"briefTitle":57,"status":123,"phases":1232,"primaryCompletion":58,"completion":82,"start":1233,"enrollment":1234,"conditions":1235,"interventions":1237},[90],"2019-07-22",40,[1236],"Flap Necrosis",[59,1238,1239,1240],"lactacte measurement","pyruvate measurement","glycerol measurement",{"intervention":1238,"totalTrials":134,"cells":1242},{"EARLY_PHASE1":1243,"PHASE1":1245,"PHASE2":1247,"PHASE3":1249,"PHASE4":1251,"NA":1253},{"trials":1244,"activeCount":98},[],{"trials":1246,"activeCount":98},[],{"trials":1248,"activeCount":98},[],{"trials":1250,"activeCount":98},[],{"trials":1252,"activeCount":98},[],{"trials":1254,"activeCount":134,"soonestReadout":58},[1255],{"nctId":56,"briefTitle":57,"status":123,"phases":1256,"primaryCompletion":58,"completion":82,"start":1233,"enrollment":1234,"conditions":1257,"interventions":1258},[90],[1236],[59,1238,1239,1240],{"intervention":1239,"totalTrials":134,"cells":1260},{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1267,"PHASE4":1269,"NA":1271},{"trials":1262,"activeCount":98},[],{"trials":1264,"activeCount":98},[],{"trials":1266,"activeCount":98},[],{"trials":1268,"activeCount":98},[],{"trials":1270,"activeCount":98},[],{"trials":1272,"activeCount":134,"soonestReadout":58},[1273],{"nctId":56,"briefTitle":57,"status":123,"phases":1274,"primaryCompletion":58,"completion":82,"start":1233,"enrollment":1234,"conditions":1275,"interventions":1276},[90],[1236],[59,1238,1239,1240],{"intervention":1240,"totalTrials":134,"cells":1278},{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1285,"PHASE4":1287,"NA":1289},{"trials":1280,"activeCount":98},[],{"trials":1282,"activeCount":98},[],{"trials":1284,"activeCount":98},[],{"trials":1286,"activeCount":98},[],{"trials":1288,"activeCount":98},[],{"trials":1290,"activeCount":134,"soonestReadout":58},[1291],{"nctId":56,"briefTitle":57,"status":123,"phases":1292,"primaryCompletion":58,"completion":82,"start":1233,"enrollment":1234,"conditions":1293,"interventions":1294},[90],[1236],[59,1238,1239,1240],{"intervention":1296,"totalTrials":134,"cells":1297},"Circulating DNA analysis",{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1308},{"trials":1299,"activeCount":98},[],{"trials":1301,"activeCount":98},[],{"trials":1303,"activeCount":98},[],{"trials":1305,"activeCount":98},[],{"trials":1307,"activeCount":98},[],{"trials":1309,"activeCount":134,"soonestReadout":1314},[1310],{"nctId":1311,"briefTitle":1312,"status":123,"phases":1313,"primaryCompletion":1314,"completion":630,"start":1315,"enrollment":1316,"conditions":1317,"interventions":1326},"NCT07471373","Pesticides and Infertility: Oxidative Stress Via Circulating Cell-free DNA and Gut\u002FGenital Microbiome Signatures in Women With Endometriosis",[90],"2028-02","2026-02-27",160,[351,1318,1319,352,1320,1321,1322,1323,1324,1325],"Infertility","Female Fertility","Genital Microbiota","Vaginal Microbiota","Endometrial Microbiota","Pesticides","Gut Microbiota","Epigenetics",[1296,1327,1328,1329,1330],"Vaginal microbiota analysis","Endometrial microbiota analysis","Intestinal microbiota analysis","Exposure to endocrine disruptors analysis",{"intervention":1327,"totalTrials":134,"cells":1332},{"EARLY_PHASE1":1333,"PHASE1":1335,"PHASE2":1337,"PHASE3":1339,"PHASE4":1341,"NA":1343},{"trials":1334,"activeCount":98},[],{"trials":1336,"activeCount":98},[],{"trials":1338,"activeCount":98},[],{"trials":1340,"activeCount":98},[],{"trials":1342,"activeCount":98},[],{"trials":1344,"activeCount":134,"soonestReadout":1314},[1345],{"nctId":1311,"briefTitle":1312,"status":123,"phases":1346,"primaryCompletion":1314,"completion":630,"start":1315,"enrollment":1316,"conditions":1347,"interventions":1348},[90],[351,1318,1319,352,1320,1321,1322,1323,1324,1325],[1296,1327,1328,1329,1330],{"intervention":1328,"totalTrials":134,"cells":1350},{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1357,"PHASE4":1359,"NA":1361},{"trials":1352,"activeCount":98},[],{"trials":1354,"activeCount":98},[],{"trials":1356,"activeCount":98},[],{"trials":1358,"activeCount":98},[],{"trials":1360,"activeCount":98},[],{"trials":1362,"activeCount":134,"soonestReadout":1314},[1363],{"nctId":1311,"briefTitle":1312,"status":123,"phases":1364,"primaryCompletion":1314,"completion":630,"start":1315,"enrollment":1316,"conditions":1365,"interventions":1366},[90],[351,1318,1319,352,1320,1321,1322,1323,1324,1325],[1296,1327,1328,1329,1330],{"intervention":1329,"totalTrials":134,"cells":1368},{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1375,"PHASE4":1377,"NA":1379},{"trials":1370,"activeCount":98},[],{"trials":1372,"activeCount":98},[],{"trials":1374,"activeCount":98},[],{"trials":1376,"activeCount":98},[],{"trials":1378,"activeCount":98},[],{"trials":1380,"activeCount":134,"soonestReadout":1314},[1381],{"nctId":1311,"briefTitle":1312,"status":123,"phases":1382,"primaryCompletion":1314,"completion":630,"start":1315,"enrollment":1316,"conditions":1383,"interventions":1384},[90],[351,1318,1319,352,1320,1321,1322,1323,1324,1325],[1296,1327,1328,1329,1330],{"intervention":1330,"totalTrials":134,"cells":1386},{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1393,"PHASE4":1395,"NA":1397},{"trials":1388,"activeCount":98},[],{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":98},[],{"trials":1394,"activeCount":98},[],{"trials":1396,"activeCount":98},[],{"trials":1398,"activeCount":134,"soonestReadout":1314},[1399],{"nctId":1311,"briefTitle":1312,"status":123,"phases":1400,"primaryCompletion":1314,"completion":630,"start":1315,"enrollment":1316,"conditions":1401,"interventions":1402},[90],[351,1318,1319,352,1320,1321,1322,1323,1324,1325],[1296,1327,1328,1329,1330],{"intervention":1404,"totalTrials":134,"cells":1405},"Furosemide intravenous titration based on natriuresis",{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1412,"PHASE4":1414,"NA":1416},{"trials":1407,"activeCount":98},[],{"trials":1409,"activeCount":98},[],{"trials":1411,"activeCount":98},[],{"trials":1413,"activeCount":98},[],{"trials":1415,"activeCount":98},[],{"trials":1417,"activeCount":134,"soonestReadout":1422},[1418],{"nctId":1419,"briefTitle":1420,"status":123,"phases":1421,"primaryCompletion":1422,"completion":1422,"start":1423,"enrollment":1424,"conditions":1425,"interventions":1430},"NCT07077772","Natriuresis-guided Depletion After Cardiac Surgery",[90],"2027-10","2025-06-25",102,[30,1426,1427,1428,1429],"Diuresis","Congestion, Venous","Sodium Depletion","Fluid Over-load",[1404,1431],"Furosemide intravenous titration based on clinical examination",{"intervention":1431,"totalTrials":134,"cells":1433},{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1438,"PHASE3":1440,"PHASE4":1442,"NA":1444},{"trials":1435,"activeCount":98},[],{"trials":1437,"activeCount":98},[],{"trials":1439,"activeCount":98},[],{"trials":1441,"activeCount":98},[],{"trials":1443,"activeCount":98},[],{"trials":1445,"activeCount":134,"soonestReadout":1422},[1446],{"nctId":1419,"briefTitle":1420,"status":123,"phases":1447,"primaryCompletion":1422,"completion":1422,"start":1423,"enrollment":1424,"conditions":1448,"interventions":1449},[90],[30,1426,1427,1428,1429],[1404,1431],{"intervention":83,"totalTrials":134,"cells":1451},{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1458,"PHASE4":1460,"NA":1462},{"trials":1453,"activeCount":98},[],{"trials":1455,"activeCount":98},[],{"trials":1457,"activeCount":98},[],{"trials":1459,"activeCount":98},[],{"trials":1461,"activeCount":98},[],{"trials":1463,"activeCount":134,"soonestReadout":82},[1464],{"nctId":80,"briefTitle":81,"status":123,"phases":1465,"primaryCompletion":82,"completion":310,"start":1466,"enrollment":1467,"conditions":1468,"interventions":1474},[90],"2024-07-09",142,[1469,1470,1471,1472,1473],"Hypnosis","Labor Pain","Virtual Reality","Labor Induction","Latent Period",[83],{"intervention":267,"totalTrials":134,"cells":1476},{"EARLY_PHASE1":1477,"PHASE1":1479,"PHASE2":1481,"PHASE3":1483,"PHASE4":1485,"NA":1487},{"trials":1478,"activeCount":98},[],{"trials":1480,"activeCount":98},[],{"trials":1482,"activeCount":98},[],{"trials":1484,"activeCount":98},[],{"trials":1486,"activeCount":98},[],{"trials":1488,"activeCount":134,"soonestReadout":259},[1489],{"nctId":256,"briefTitle":257,"status":123,"phases":1490,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":1491,"interventions":1492},[90],[264,265],[267,150],{"intervention":436,"totalTrials":134,"cells":1494},{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1499,"PHASE3":1501,"PHASE4":1503,"NA":1505},{"trials":1496,"activeCount":98},[],{"trials":1498,"activeCount":98},[],{"trials":1500,"activeCount":98},[],{"trials":1502,"activeCount":98},[],{"trials":1504,"activeCount":98},[],{"trials":1506,"activeCount":134,"soonestReadout":384},[1507],{"nctId":424,"briefTitle":425,"status":123,"phases":1508,"primaryCompletion":384,"completion":427,"start":428,"enrollment":429,"conditions":1509,"interventions":1510},[90],[431,432,433,434],[436,398],{"intervention":1512,"totalTrials":134,"cells":1513},"blood retriewal",{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1520,"PHASE4":1522,"NA":1524},{"trials":1515,"activeCount":98},[],{"trials":1517,"activeCount":98},[],{"trials":1519,"activeCount":98},[],{"trials":1521,"activeCount":98},[],{"trials":1523,"activeCount":98},[],{"trials":1525,"activeCount":134,"soonestReadout":142},[1526],{"nctId":1527,"briefTitle":1528,"status":123,"phases":1529,"primaryCompletion":142,"completion":142,"start":1530,"enrollment":300,"conditions":1531,"interventions":1536},"NCT05813418","Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment",[90],"2021-07-02",[1532,1533,1534,1535],"Immunotherapy","Immune Checkpoint Inhibitors","Immune-related Adverse Event","Predictive Biomarkers",[1512],{"intervention":49,"totalTrials":134,"cells":1538},{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1545,"PHASE4":1547,"NA":1549},{"trials":1540,"activeCount":98},[],{"trials":1542,"activeCount":98},[],{"trials":1544,"activeCount":98},[],{"trials":1546,"activeCount":98},[],{"trials":1548,"activeCount":98},[],{"trials":1550,"activeCount":134,"soonestReadout":48},[1551],{"nctId":46,"briefTitle":47,"status":140,"phases":1552,"primaryCompletion":48,"completion":247,"start":1553,"enrollment":21,"conditions":1554,"interventions":1557},[90],"2021-02-02",[1555,1556],"Deep Vein Thrombosis","Inflammatory Response",[49],{"intervention":1559,"totalTrials":134,"cells":1560},"ofloxacin",{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1562,"activeCount":98},[],{"trials":1564,"activeCount":98},[],{"trials":1566,"activeCount":98},[],{"trials":1568,"activeCount":98},[],{"trials":1570,"activeCount":98},[],{"trials":1572,"activeCount":134,"soonestReadout":1577},[1573],{"nctId":1574,"briefTitle":1575,"status":123,"phases":1576,"primaryCompletion":1577,"completion":165,"start":1578,"enrollment":1579,"conditions":1580,"interventions":1585},"NCT04496024","Ofloxacin Concentration-toxicity Relationship in the Elderly",[90],"2026-06","2020-06-02",110,[1581,1582,1583,1584],"Ofloxacin","Bone and Joint Infection","Therapeutic Drug Monitoring","Adverse Drug Reactions",[1559,1586],"Ofloxacin Serum concentration",{"intervention":1586,"totalTrials":134,"cells":1588},{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1595,"PHASE4":1597,"NA":1599},{"trials":1590,"activeCount":98},[],{"trials":1592,"activeCount":98},[],{"trials":1594,"activeCount":98},[],{"trials":1596,"activeCount":98},[],{"trials":1598,"activeCount":98},[],{"trials":1600,"activeCount":134,"soonestReadout":1577},[1601],{"nctId":1574,"briefTitle":1575,"status":123,"phases":1602,"primaryCompletion":1577,"completion":165,"start":1578,"enrollment":1579,"conditions":1603,"interventions":1604},[90],[1581,1582,1583,1584],[1559,1586],{"intervention":1606,"totalTrials":134,"cells":1607},"blood redrawal",{"EARLY_PHASE1":1608,"PHASE1":1610,"PHASE2":1612,"PHASE3":1614,"PHASE4":1616,"NA":1618},{"trials":1609,"activeCount":98},[],{"trials":1611,"activeCount":98},[],{"trials":1613,"activeCount":98},[],{"trials":1615,"activeCount":98},[],{"trials":1617,"activeCount":98},[],{"trials":1619,"activeCount":134,"soonestReadout":1624},[1620],{"nctId":1621,"briefTitle":1622,"status":123,"phases":1623,"primaryCompletion":1624,"completion":1624,"start":1625,"enrollment":287,"conditions":1626,"interventions":1630},"NCT07459816","Genomic of CONgenital Sideroblastic Anemias",[90],"2026-11","2025-10-28",[1627,1628,1629],"Anemia","Genetics","Erythropoiesis",[1606],{"intervention":1632,"totalTrials":134,"cells":1633},"Formoterol Fumarate 12 mcg",{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1638,"PHASE3":1640,"PHASE4":1642,"NA":1644},{"trials":1635,"activeCount":98},[],{"trials":1637,"activeCount":98},[],{"trials":1639,"activeCount":98},[],{"trials":1641,"activeCount":98},[],{"trials":1643,"activeCount":98},[],{"trials":1645,"activeCount":134,"soonestReadout":285},[1646],{"nctId":1647,"briefTitle":1648,"status":123,"phases":1649,"primaryCompletion":285,"completion":454,"start":1650,"enrollment":1651,"conditions":1652,"interventions":1654},"NCT06865040","Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications",[90],"2025-07-31",266,[25,1653],"Postoperative Pulmonary Complications (PPCs)",[1632],{"intervention":1656,"totalTrials":134,"cells":1657},"sample of bone marrow cells",{"EARLY_PHASE1":1658,"PHASE1":1660,"PHASE2":1662,"PHASE3":1664,"PHASE4":1666,"NA":1668},{"trials":1659,"activeCount":98},[],{"trials":1661,"activeCount":98},[],{"trials":1663,"activeCount":98},[],{"trials":1665,"activeCount":98},[],{"trials":1667,"activeCount":98},[],{"trials":1669,"activeCount":134,"soonestReadout":285},[1670],{"nctId":1671,"briefTitle":1672,"status":123,"phases":1673,"primaryCompletion":285,"completion":285,"start":1674,"enrollment":115,"conditions":1675,"interventions":1677},"NCT07471074","Phenotypic and Functional Study of Bone Marrow Mesenchymal Stem Cells in Waldenström Macroglobulinemia",[90],"2026-02-10",[1676],"Waldenström Macroglobuloinemia",[1656],{"intervention":1679,"totalTrials":134,"cells":1680},"blood microsampling",{"EARLY_PHASE1":1681,"PHASE1":1683,"PHASE2":1685,"PHASE3":1687,"PHASE4":1689,"NA":1691},{"trials":1682,"activeCount":98},[],{"trials":1684,"activeCount":98},[],{"trials":1686,"activeCount":98},[],{"trials":1688,"activeCount":98},[],{"trials":1690,"activeCount":98},[],{"trials":1692,"activeCount":134,"soonestReadout":329},[1693],{"nctId":1694,"briefTitle":1695,"status":123,"phases":1696,"primaryCompletion":329,"completion":1697,"start":1698,"enrollment":1699,"conditions":1700,"interventions":1703},"NCT06084832","Smartphone Application for University Students With Binge Drinking Behavior",[90],"2026-07","2023-10-01",628,[1701,1702],"Alcohol Drinking","Binge Drinking",[1679],{"intervention":39,"totalTrials":134,"cells":1705},{"EARLY_PHASE1":1706,"PHASE1":1708,"PHASE2":1710,"PHASE3":1712,"PHASE4":1714,"NA":1716},{"trials":1707,"activeCount":98},[],{"trials":1709,"activeCount":98},[],{"trials":1711,"activeCount":98},[],{"trials":1713,"activeCount":98},[],{"trials":1715,"activeCount":98},[],{"trials":1717,"activeCount":134,"soonestReadout":38},[1718],{"nctId":36,"briefTitle":37,"status":140,"phases":1719,"primaryCompletion":38,"completion":1720,"start":1721,"enrollment":1722,"conditions":1723,"interventions":1725},[90],"2026-06-01","2019-04-23",101,[398,1724],"Pneumonia",[39,1726],"blood test to measure plasmatic antibiotic concentration in µg\u002Fml",{"intervention":1726,"totalTrials":134,"cells":1728},{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1733,"PHASE3":1735,"PHASE4":1737,"NA":1739},{"trials":1730,"activeCount":98},[],{"trials":1732,"activeCount":98},[],{"trials":1734,"activeCount":98},[],{"trials":1736,"activeCount":98},[],{"trials":1738,"activeCount":98},[],{"trials":1740,"activeCount":134,"soonestReadout":38},[1741],{"nctId":36,"briefTitle":37,"status":140,"phases":1742,"primaryCompletion":38,"completion":1720,"start":1721,"enrollment":1722,"conditions":1743,"interventions":1744},[90],[398,1724],[39,1726],{"intervention":1746,"totalTrials":134,"cells":1747},"identification of genetic factors",{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1752,"PHASE3":1754,"PHASE4":1756,"NA":1758},{"trials":1749,"activeCount":98},[],{"trials":1751,"activeCount":98},[],{"trials":1753,"activeCount":98},[],{"trials":1755,"activeCount":98},[],{"trials":1757,"activeCount":98},[],{"trials":1759,"activeCount":134,"soonestReadout":1764},[1760],{"nctId":1761,"briefTitle":1762,"status":123,"phases":1763,"primaryCompletion":1764,"completion":1764,"start":1765,"enrollment":473,"conditions":1766,"interventions":1768},"NCT03065686","Identification of Genetic Factors Implicated in Orofacial Cleft Using Whole Exome Sequencing",[90],"2027-11-30","2016-11-30",[1767],"Cleft Lip and Palate",[1746],{"intervention":78,"totalTrials":134,"cells":1770},{"EARLY_PHASE1":1771,"PHASE1":1773,"PHASE2":1775,"PHASE3":1777,"PHASE4":1779,"NA":1781},{"trials":1772,"activeCount":98},[],{"trials":1774,"activeCount":98},[],{"trials":1776,"activeCount":98},[],{"trials":1778,"activeCount":98},[],{"trials":1780,"activeCount":98},[],{"trials":1782,"activeCount":134,"soonestReadout":73},[1783],{"nctId":76,"briefTitle":77,"status":123,"phases":1784,"primaryCompletion":73,"completion":82,"start":1785,"enrollment":1467,"conditions":1786,"interventions":1789},[90],"2023-09-01",[1787,277,1788,20],"Vasoplegia","Norepinephrine",[78,1790],"norepinephrine weaning protocol and guided by the HPI",{"intervention":1790,"totalTrials":134,"cells":1792},{"EARLY_PHASE1":1793,"PHASE1":1795,"PHASE2":1797,"PHASE3":1799,"PHASE4":1801,"NA":1803},{"trials":1794,"activeCount":98},[],{"trials":1796,"activeCount":98},[],{"trials":1798,"activeCount":98},[],{"trials":1800,"activeCount":98},[],{"trials":1802,"activeCount":98},[],{"trials":1804,"activeCount":134,"soonestReadout":73},[1805],{"nctId":76,"briefTitle":77,"status":123,"phases":1806,"primaryCompletion":73,"completion":82,"start":1785,"enrollment":1467,"conditions":1807,"interventions":1808},[90],[1787,277,1788,20],[78,1790],{"intervention":64,"totalTrials":134,"cells":1810},{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1815,"PHASE3":1817,"PHASE4":1819,"NA":1821},{"trials":1812,"activeCount":98},[],{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":98},[],{"trials":1818,"activeCount":98},[],{"trials":1820,"activeCount":98},[],{"trials":1822,"activeCount":134,"soonestReadout":63},[1823],{"nctId":61,"briefTitle":62,"status":123,"phases":1824,"primaryCompletion":63,"completion":1825,"start":1826,"enrollment":473,"conditions":1827,"interventions":1830},[90],"2026-05","2024-09-25",[1828,1829],"Formaldehyde","Pathological Anatomy and Cytology",[64],{"intervention":1832,"totalTrials":134,"cells":1833},"Blood and urine samples",{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1840,"PHASE4":1842,"NA":1844},{"trials":1835,"activeCount":98},[],{"trials":1837,"activeCount":98},[],{"trials":1839,"activeCount":98},[],{"trials":1841,"activeCount":98},[],{"trials":1843,"activeCount":98},[],{"trials":1845,"activeCount":134,"soonestReadout":1850},[1846],{"nctId":1847,"briefTitle":1848,"status":123,"phases":1849,"primaryCompletion":1850,"completion":1851,"start":1852,"enrollment":1853,"conditions":1854,"interventions":1857},"NCT05237063","Prediction of Recurrence and Complications of Nephrolithiasis Using a Precision Medicine Approach",[90],"2026-02","2031-02","2021-01-13",2000,[1855,1856],"Kidney Stone","Nephrolithiasis",[1832],{"intervention":1859,"totalTrials":134,"cells":1860},"Salivary self-collection",{"EARLY_PHASE1":1861,"PHASE1":1863,"PHASE2":1865,"PHASE3":1867,"PHASE4":1869,"NA":1871},{"trials":1862,"activeCount":98},[],{"trials":1864,"activeCount":98},[],{"trials":1866,"activeCount":98},[],{"trials":1868,"activeCount":98},[],{"trials":1870,"activeCount":98},[],{"trials":1872,"activeCount":134,"soonestReadout":272},[1873],{"nctId":1874,"briefTitle":1875,"status":451,"phases":1876,"primaryCompletion":272,"completion":453,"start":142,"enrollment":249,"conditions":1877,"interventions":1883},"NCT07256470","Salivary Replication of BK Virus in Post-kidney Transplant",[90],[1878,1879,1880,1881,1882],"BK Virus","Salivary Replication","Kidney Transplantation","Nephropathy","DNAemia",[1859],{"intervention":477,"totalTrials":134,"cells":1885},{"EARLY_PHASE1":1886,"PHASE1":1888,"PHASE2":1890,"PHASE3":1892,"PHASE4":1894,"NA":1900},{"trials":1887,"activeCount":98},[],{"trials":1889,"activeCount":98},[],{"trials":1891,"activeCount":98},[],{"trials":1893,"activeCount":98},[],{"trials":1895,"activeCount":98},[1896],{"nctId":468,"briefTitle":469,"status":221,"phases":1897,"primaryCompletion":471,"completion":471,"start":472,"enrollment":473,"conditions":1898,"interventions":1899},[89],[475],[438,477],{"trials":1901,"activeCount":98},[],{"intervention":1903,"totalTrials":134,"cells":1904},"ropivacaïne",{"EARLY_PHASE1":1905,"PHASE1":1907,"PHASE2":1909,"PHASE3":1911,"PHASE4":1913,"NA":1925},{"trials":1906,"activeCount":98},[],{"trials":1908,"activeCount":98},[],{"trials":1910,"activeCount":98},[],{"trials":1912,"activeCount":98},[],{"trials":1914,"activeCount":98},[1915],{"nctId":1916,"briefTitle":1917,"status":221,"phases":1918,"primaryCompletion":1919,"completion":1919,"start":1920,"enrollment":115,"conditions":1921,"interventions":1923},"NCT01935596","Comparative Study of the Effects of Two Local Anesthetics Administered Intrathecally: 0.5% Levobupivacaine and Ropivacaine 0.5%",[89],"2014-04","2013-05",[1922],"Patients Undergoing Lower Limb Surgery",[1903,1924],"lévobupivacaïne",{"trials":1926,"activeCount":98},[],{"intervention":1924,"totalTrials":134,"cells":1928},{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1935,"PHASE4":1937,"NA":1943},{"trials":1930,"activeCount":98},[],{"trials":1932,"activeCount":98},[],{"trials":1934,"activeCount":98},[],{"trials":1936,"activeCount":98},[],{"trials":1938,"activeCount":98},[1939],{"nctId":1916,"briefTitle":1917,"status":221,"phases":1940,"primaryCompletion":1919,"completion":1919,"start":1920,"enrollment":115,"conditions":1941,"interventions":1942},[89],[1922],[1903,1924],{"trials":1944,"activeCount":98},[],{"intervention":1946,"totalTrials":134,"cells":1947},"Tacrolimus",{"EARLY_PHASE1":1948,"PHASE1":1950,"PHASE2":1952,"PHASE3":1954,"PHASE4":1956,"NA":1968},{"trials":1949,"activeCount":98},[],{"trials":1951,"activeCount":98},[],{"trials":1953,"activeCount":98},[],{"trials":1955,"activeCount":98},[],{"trials":1957,"activeCount":98},[1958],{"nctId":1959,"briefTitle":1960,"status":221,"phases":1961,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":1966,"interventions":1967},"NCT00552201","TACrolimus in Renal Transplantation: Individualization by Pharmacogenetic",[89],"2008-01","2008-12","2006-04",280,[1880],[1946],{"trials":1969,"activeCount":98},[],{"intervention":492,"totalTrials":134,"cells":1971},{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1976,"PHASE3":1978,"PHASE4":1980,"NA":1986},{"trials":1973,"activeCount":98},[],{"trials":1975,"activeCount":98},[],{"trials":1977,"activeCount":98},[],{"trials":1979,"activeCount":98},[],{"trials":1981,"activeCount":98},[1982],{"nctId":479,"briefTitle":480,"status":221,"phases":1983,"primaryCompletion":482,"completion":483,"start":484,"enrollment":485,"conditions":1984,"interventions":1985},[89],[487,488,489,490],[492,438],{"trials":1987,"activeCount":98},[],{"intervention":1989,"totalTrials":134,"cells":1990},"Transversus Abdominis Plane",{"EARLY_PHASE1":1991,"PHASE1":1993,"PHASE2":1995,"PHASE3":1997,"PHASE4":1999,"NA":2011},{"trials":1992,"activeCount":98},[],{"trials":1994,"activeCount":98},[],{"trials":1996,"activeCount":98},[],{"trials":1998,"activeCount":98},[],{"trials":2000,"activeCount":98},[2001],{"nctId":2002,"briefTitle":2003,"status":221,"phases":2004,"primaryCompletion":2005,"start":2006,"enrollment":202,"conditions":2007,"interventions":2009},"NCT01628952","Comparison of the Bilateral TAP Block Versus Curare in Muscle Relaxation of the Abdominal Wall During Laparoscopic Digestive Surgery: Prospective Randomized Study",[89],"2013-01","2012-06",[2008],"The Main of This Study is to Compare the Nerve Block of the Muscles of the Abdominal Wall Between the Bilateral TAP Block and Curare",[1989,2010],"Curare",{"trials":2012,"activeCount":98},[],{"intervention":2010,"totalTrials":134,"cells":2014},{"EARLY_PHASE1":2015,"PHASE1":2017,"PHASE2":2019,"PHASE3":2021,"PHASE4":2023,"NA":2029},{"trials":2016,"activeCount":98},[],{"trials":2018,"activeCount":98},[],{"trials":2020,"activeCount":98},[],{"trials":2022,"activeCount":98},[],{"trials":2024,"activeCount":98},[2025],{"nctId":2002,"briefTitle":2003,"status":221,"phases":2026,"primaryCompletion":2005,"start":2006,"enrollment":202,"conditions":2027,"interventions":2028},[89],[2008],[1989,2010],{"trials":2030,"activeCount":98},[],{"intervention":2032,"totalTrials":134,"cells":2033},"Neorecormon",{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2040,"PHASE4":2042,"NA":2057},{"trials":2035,"activeCount":98},[],{"trials":2037,"activeCount":98},[],{"trials":2039,"activeCount":98},[],{"trials":2041,"activeCount":98},[],{"trials":2043,"activeCount":98},[2044],{"nctId":2045,"briefTitle":2046,"status":221,"phases":2047,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":2052,"interventions":2056},"NCT00396435","Correction of Anaemia and Progression of Renal Failure on Transplanted Patients",[89],"2009-04","2010-05","2004-04",128,[2053,2054,2055],"Anaemia","Renal Transplantation","Kidney Failure",[2032],{"trials":2058,"activeCount":98},[],{"intervention":1788,"totalTrials":356,"cells":2060},{"EARLY_PHASE1":2061,"PHASE1":2063,"PHASE2":2065,"PHASE3":2067,"PHASE4":2092,"NA":2094},{"trials":2062,"activeCount":98},[],{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[],{"trials":2068,"activeCount":98},[2069,2079],{"nctId":2070,"briefTitle":2071,"status":221,"phases":2072,"primaryCompletion":2073,"completion":2073,"start":2074,"enrollment":2075,"conditions":2076,"interventions":2078},"NCT02479529","Weaning of Norepinephrine Guided by the Dynamic Arterial Compliance in Cardiac Surgery Post Operative.",[88],"2016-06","2014-10",130,[2077],"Vasoplegic Syndrome",[1788,1788],{"nctId":2080,"briefTitle":2081,"status":221,"phases":2082,"primaryCompletion":2083,"completion":2084,"start":2085,"enrollment":187,"conditions":2086,"interventions":2090},"NCT05276596","Evaluation of the Early Use of Norepinephrine in Major Abdominal Surgery on Postoperative Organ Dysfunction",[88],"2024-12-17","2025-11-29","2021-11-17",[1788,2087,2088,2089],"Hypotension","Anesthesiology","Major Abdominal Surgery",[2091,1788],"Ephedrine",{"trials":2093,"activeCount":98},[],{"trials":2095,"activeCount":98},[],{"intervention":2097,"totalTrials":134,"cells":2098},"methylene blue",{"EARLY_PHASE1":2099,"PHASE1":2101,"PHASE2":2103,"PHASE3":2105,"PHASE4":2116,"NA":2118},{"trials":2100,"activeCount":98},[],{"trials":2102,"activeCount":98},[],{"trials":2104,"activeCount":98},[],{"trials":2106,"activeCount":98},[2107],{"nctId":2108,"briefTitle":2109,"status":221,"phases":2110,"primaryCompletion":2111,"completion":2111,"start":2112,"enrollment":300,"conditions":2113,"interventions":2115},"NCT01847612","Use of Indocyanine Green Cholangiography and Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy",[88],"2025-07-03","2013-07-08",[2114],"Liver Disease",[2097],{"trials":2117,"activeCount":98},[],{"trials":2119,"activeCount":98},[],{"intervention":2121,"totalTrials":134,"cells":2122},"loco-regional anesthesia serratus plane bloc",{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2127,"PHASE3":2129,"PHASE4":2143,"NA":2145},{"trials":2124,"activeCount":98},[],{"trials":2126,"activeCount":98},[],{"trials":2128,"activeCount":98},[],{"trials":2130,"activeCount":98},[2131],{"nctId":2132,"briefTitle":2133,"status":221,"phases":2134,"primaryCompletion":2135,"completion":2135,"start":2136,"enrollment":1195,"conditions":2137,"interventions":2140},"NCT04222010","Serratus Plain Block Versus Paravertebral Block Versus Serratus Plain Block and Paravertebral Block for Postoperative Pain Following Thoracoscopic Surgery",[88],"2023-02-22","2020-01-02",[2138,2139],"Anesthesia, Local","Pain, Postoperative",[2121,2141,2142],"Loco-regional anesthesia : paravertebral bloc","Loco-regional anesthesia : serratus plane bloc",{"trials":2144,"activeCount":98},[],{"trials":2146,"activeCount":98},[],{"intervention":2141,"totalTrials":134,"cells":2148},{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2155,"PHASE4":2161,"NA":2163},{"trials":2150,"activeCount":98},[],{"trials":2152,"activeCount":98},[],{"trials":2154,"activeCount":98},[],{"trials":2156,"activeCount":98},[2157],{"nctId":2132,"briefTitle":2133,"status":221,"phases":2158,"primaryCompletion":2135,"completion":2135,"start":2136,"enrollment":1195,"conditions":2159,"interventions":2160},[88],[2138,2139],[2121,2141,2142],{"trials":2162,"activeCount":98},[],{"trials":2164,"activeCount":98},[],{"intervention":2142,"totalTrials":134,"cells":2166},{"EARLY_PHASE1":2167,"PHASE1":2169,"PHASE2":2171,"PHASE3":2173,"PHASE4":2179,"NA":2181},{"trials":2168,"activeCount":98},[],{"trials":2170,"activeCount":98},[],{"trials":2172,"activeCount":98},[],{"trials":2174,"activeCount":98},[2175],{"nctId":2132,"briefTitle":2133,"status":221,"phases":2176,"primaryCompletion":2135,"completion":2135,"start":2136,"enrollment":1195,"conditions":2177,"interventions":2178},[88],[2138,2139],[2121,2141,2142],{"trials":2180,"activeCount":98},[],{"trials":2182,"activeCount":98},[],{"intervention":2184,"totalTrials":134,"cells":2185},"L-Thyroxine",{"EARLY_PHASE1":2186,"PHASE1":2188,"PHASE2":2190,"PHASE3":2192,"PHASE4":2205,"NA":2207},{"trials":2187,"activeCount":98},[],{"trials":2189,"activeCount":98},[],{"trials":2191,"activeCount":98},[],{"trials":2193,"activeCount":98},[2194],{"nctId":2195,"briefTitle":2196,"status":221,"phases":2197,"primaryCompletion":2198,"completion":2199,"start":2200,"enrollment":115,"conditions":2201,"interventions":2203},"NCT01306227","L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia",[88],"2014-12-31","2017-12-31","2006-09-01",[2202],"Hypothyroxinemia",[2184,2204],"water",{"trials":2206,"activeCount":98},[],{"trials":2208,"activeCount":98},[],{"intervention":2204,"totalTrials":134,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2215,"PHASE3":2217,"PHASE4":2223,"NA":2225},{"trials":2212,"activeCount":98},[],{"trials":2214,"activeCount":98},[],{"trials":2216,"activeCount":98},[],{"trials":2218,"activeCount":98},[2219],{"nctId":2195,"briefTitle":2196,"status":221,"phases":2220,"primaryCompletion":2198,"completion":2199,"start":2200,"enrollment":115,"conditions":2221,"interventions":2222},[88],[2202],[2184,2204],{"trials":2224,"activeCount":98},[],{"trials":2226,"activeCount":98},[],{"intervention":2228,"totalTrials":134,"cells":2229},"Amoxicillin clavulanic acid",{"EARLY_PHASE1":2230,"PHASE1":2232,"PHASE2":2234,"PHASE3":2236,"PHASE4":2250,"NA":2252},{"trials":2231,"activeCount":98},[],{"trials":2233,"activeCount":98},[],{"trials":2235,"activeCount":98},[],{"trials":2237,"activeCount":98},[2238],{"nctId":2239,"briefTitle":2240,"status":221,"phases":2241,"primaryCompletion":2242,"completion":2242,"start":2049,"enrollment":2243,"conditions":2244,"interventions":2249},"NCT01015417","Place of Antibiotics in the Postoperative Acute Lithiasic Cholecystitis",[88],"2012-11",414,[2245,2246,2247,2248],"Acute Lithiasic Cholecystitis Grade I or II","Symptoms Lasting for Less Than 5 Days","Required Cholecystectomy","Preoperative Amoxicillin Clavulanic Acid for at Most 5 Days",[2228],{"trials":2251,"activeCount":98},[],{"trials":2253,"activeCount":98},[],{"intervention":2255,"totalTrials":134,"cells":2256},"florbetapir",{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2263,"PHASE4":2275,"NA":2277},{"trials":2258,"activeCount":98},[],{"trials":2260,"activeCount":98},[],{"trials":2262,"activeCount":98},[],{"trials":2264,"activeCount":98},[2265],{"nctId":2266,"briefTitle":2267,"status":110,"phases":2268,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":249,"conditions":2271,"interventions":2274},"NCT02813434","Cerebral Amyloid Imaging Using Florbetapir (AV-45)",[88],"2022-09","2014-09",[2272,2273],"Dementia","Cognition Disorders",[2255],{"trials":2276,"activeCount":98},[],{"trials":2278,"activeCount":98},[],{"intervention":2280,"totalTrials":134,"cells":2281},"tisseel",{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2288,"PHASE4":2300,"NA":2302},{"trials":2283,"activeCount":98},[],{"trials":2285,"activeCount":98},[],{"trials":2287,"activeCount":98},[],{"trials":2289,"activeCount":98},[2290],{"nctId":2291,"briefTitle":2292,"status":221,"phases":2293,"primaryCompletion":2294,"completion":2294,"start":2295,"enrollment":2296,"conditions":2297,"interventions":2299},"NCT01613664","Efficiency of TISSEEL for Sleeve Gastrectomy Complications",[88],"2018-05-15","2014-02",597,[2298],"Morbid Obesity",[2280],{"trials":2301,"activeCount":98},[],{"trials":2303,"activeCount":98},[],{"intervention":2305,"totalTrials":134,"cells":2306},"Nalmefene (Selincro®) 18 mg",{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2313,"PHASE4":2326,"NA":2328},{"trials":2308,"activeCount":98},[],{"trials":2310,"activeCount":98},[],{"trials":2312,"activeCount":98},[],{"trials":2314,"activeCount":98},[2315],{"nctId":2316,"briefTitle":2317,"status":1111,"phases":2318,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":98,"conditions":2321,"interventions":2325},"NCT02824354","Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.",[88],"2022-12-01","2018-12-01",[2322,2323,2324],"Cirrhosis","Alcohol Dependence","Nalmefene",[2305],{"trials":2327,"activeCount":98},[],{"trials":2329,"activeCount":98},[],{"intervention":2091,"totalTrials":134,"cells":2331},{"EARLY_PHASE1":2332,"PHASE1":2334,"PHASE2":2336,"PHASE3":2338,"PHASE4":2344,"NA":2346},{"trials":2333,"activeCount":98},[],{"trials":2335,"activeCount":98},[],{"trials":2337,"activeCount":98},[],{"trials":2339,"activeCount":98},[2340],{"nctId":2080,"briefTitle":2081,"status":221,"phases":2341,"primaryCompletion":2083,"completion":2084,"start":2085,"enrollment":187,"conditions":2342,"interventions":2343},[88],[1788,2087,2088,2089],[2091,1788],{"trials":2345,"activeCount":98},[],{"trials":2347,"activeCount":98},[],{"intervention":2349,"totalTrials":134,"cells":2350},"Azithromycin",{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2357,"PHASE4":2370,"NA":2372},{"trials":2352,"activeCount":98},[],{"trials":2354,"activeCount":98},[],{"trials":2356,"activeCount":98},[],{"trials":2358,"activeCount":98},[2359],{"nctId":2360,"briefTitle":2361,"status":2362,"phases":2363,"primaryCompletion":2364,"completion":346,"start":2365,"enrollment":2366,"conditions":2367,"interventions":2369},"NCT04371107","Proactive Care of Ambulatory COVID19 Patients","SUSPENDED",[88],"2020-06-01","2020-04-29",11,[15,2349,2368],"Ambulatory",[2349],{"trials":2371,"activeCount":98},[],{"trials":2373,"activeCount":98},[],{"intervention":2375,"totalTrials":134,"cells":2376},"Variation of behaviors of Parkinson's disease",{"EARLY_PHASE1":2377,"PHASE1":2379,"PHASE2":2381,"PHASE3":2383,"PHASE4":2395,"NA":2397},{"trials":2378,"activeCount":98},[],{"trials":2380,"activeCount":98},[],{"trials":2382,"activeCount":98},[],{"trials":2384,"activeCount":98},[2385],{"nctId":2386,"briefTitle":2387,"status":110,"phases":2388,"primaryCompletion":2389,"completion":2389,"start":2390,"enrollment":768,"conditions":2391,"interventions":2394},"NCT03146130","Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders",[88],"2019-12-20","2018-07-05",[2392,2393],"Impulse Control Disorder","Parkinson",[2375],{"trials":2396,"activeCount":98},[],{"trials":2398,"activeCount":98},[],{"intervention":2400,"totalTrials":134,"cells":2401},"Vitamin C",{"EARLY_PHASE1":2402,"PHASE1":2404,"PHASE2":2406,"PHASE3":2408,"PHASE4":2420,"NA":2422},{"trials":2403,"activeCount":98},[],{"trials":2405,"activeCount":98},[],{"trials":2407,"activeCount":98},[],{"trials":2409,"activeCount":98},[2410],{"nctId":2411,"briefTitle":2412,"status":110,"phases":2413,"primaryCompletion":2414,"completion":58,"start":2415,"enrollment":2416,"conditions":2417,"interventions":2419},"NCT02390505","Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery",[88],"2023-12","2016-07-18",1000,[2418],"Complex Regional Pain Syndrome (CRPS) TYPE I",[2400],{"trials":2421,"activeCount":98},[],{"trials":2423,"activeCount":98},[],{"intervention":2425,"totalTrials":134,"cells":2426},"epoetin beta",{"EARLY_PHASE1":2427,"PHASE1":2429,"PHASE2":2431,"PHASE3":2433,"PHASE4":2444,"NA":2446},{"trials":2428,"activeCount":98},[],{"trials":2430,"activeCount":98},[],{"trials":2432,"activeCount":98},[],{"trials":2434,"activeCount":98},[2435],{"nctId":2436,"briefTitle":2437,"status":221,"phases":2438,"primaryCompletion":2048,"completion":2439,"start":2440,"enrollment":2441,"conditions":2442,"interventions":2443},"NCT00815867","Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant",[88],"2009-09","2007-10",108,[2055],[2425],{"trials":2445,"activeCount":98},[],{"trials":2447,"activeCount":98},[],{"intervention":2449,"totalTrials":134,"cells":2450},"Assess the efficacy and side effects of Misoprostol according to the route of administration",{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2455,"PHASE3":2457,"PHASE4":2469,"NA":2471},{"trials":2452,"activeCount":98},[],{"trials":2454,"activeCount":98},[],{"trials":2456,"activeCount":98},[],{"trials":2458,"activeCount":98},[2459],{"nctId":2460,"briefTitle":2461,"status":1111,"phases":2462,"primaryCompletion":2463,"completion":2463,"start":2464,"enrollment":98,"conditions":2465,"interventions":2468},"NCT03140384","Compare the Different Routes of Administration of Misoprostol During Medicinal Abortion Between 7 and 9 Weeks of Amenorrhoea (SA)",[88],"2019-07-20","2017-08-20",[2466,2467],"Misoprostol","Drug-induced Abortion",[2449],{"trials":2470,"activeCount":98},[],{"trials":2472,"activeCount":98},[],{"intervention":2474,"totalTrials":134,"cells":2475},"3,4-diaminopyridine",{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2480,"PHASE3":2482,"PHASE4":2494,"NA":2496},{"trials":2477,"activeCount":98},[],{"trials":2479,"activeCount":98},[],{"trials":2481,"activeCount":98},[],{"trials":2483,"activeCount":98},[2484],{"nctId":2485,"briefTitle":2486,"status":221,"phases":2487,"primaryCompletion":2488,"completion":2489,"start":2490,"enrollment":94,"conditions":2491,"interventions":2493},"NCT01441557","Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism",[87,88],"2012-02","2012-03","2011-09",[2492],"Botulism",[2474],{"trials":2495,"activeCount":98},[],{"trials":2497,"activeCount":98},[],{"intervention":2499,"totalTrials":134,"cells":2500},"Venous puncture in elderly patients",{"EARLY_PHASE1":2501,"PHASE1":2503,"PHASE2":2505,"PHASE3":2507,"PHASE4":2520,"NA":2522},{"trials":2502,"activeCount":98},[],{"trials":2504,"activeCount":98},[],{"trials":2506,"activeCount":98},[],{"trials":2508,"activeCount":98},[2509],{"nctId":2510,"briefTitle":2511,"status":221,"phases":2512,"primaryCompletion":2513,"completion":2514,"start":2515,"enrollment":331,"conditions":2516,"interventions":2519},"NCT03139045","Impact of VeinViewer® Vision to Guide Peripheral Venipuncture in Geriatrics",[88],"2019-09-01","2021-12-01","2018-09-01",[2517,2518],"Venipuncture","Geriatric",[2499],{"trials":2521,"activeCount":98},[],{"trials":2523,"activeCount":98},[],{"intervention":2525,"totalTrials":134,"cells":2526},"Clarithromycin",{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2533,"PHASE4":2546,"NA":2548},{"trials":2528,"activeCount":98},[],{"trials":2530,"activeCount":98},[],{"trials":2532,"activeCount":98},[],{"trials":2534,"activeCount":98},[2535],{"nctId":2536,"briefTitle":2537,"status":221,"phases":2538,"primaryCompletion":2539,"completion":2539,"start":2540,"enrollment":2541,"conditions":2542,"interventions":2544},"NCT01298336","Treatment of Mycobacterium Xenopi Pulmonary Infection",[88],"2019-03","2011-03-02",92,[2543],"Atypical; Mycobacterium, Pulmonary, Tuberculous",[2525,2545],"Moxifloxacin",{"trials":2547,"activeCount":98},[],{"trials":2549,"activeCount":98},[],{"intervention":2545,"totalTrials":134,"cells":2551},{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2558,"PHASE4":2564,"NA":2566},{"trials":2553,"activeCount":98},[],{"trials":2555,"activeCount":98},[],{"trials":2557,"activeCount":98},[],{"trials":2559,"activeCount":98},[2560],{"nctId":2536,"briefTitle":2537,"status":221,"phases":2561,"primaryCompletion":2539,"completion":2539,"start":2540,"enrollment":2541,"conditions":2562,"interventions":2563},[88],[2543],[2525,2545],{"trials":2565,"activeCount":98},[],{"trials":2567,"activeCount":98},[],{"intervention":2569,"totalTrials":134,"cells":2570},"medical oxygen",{"EARLY_PHASE1":2571,"PHASE1":2573,"PHASE2":2575,"PHASE3":2577,"PHASE4":2590,"NA":2592},{"trials":2572,"activeCount":98},[],{"trials":2574,"activeCount":98},[],{"trials":2576,"activeCount":98},[],{"trials":2578,"activeCount":98},[2579],{"nctId":2580,"briefTitle":2581,"status":221,"phases":2582,"primaryCompletion":2583,"completion":2584,"start":2585,"enrollment":2586,"conditions":2587,"interventions":2589},"NCT02819739","Impact of Hyperoxia During Cardiopulmonary",[88],"2018-10-10","2019-03-30","2014-11-11",330,[2588],"Cardiac Complications",[2569],{"trials":2591,"activeCount":98},[],{"trials":2593,"activeCount":98},[],{"intervention":2595,"totalTrials":134,"cells":2596},"cyclosporin + mycophenolate mofetil",{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2603,"PHASE4":2614,"NA":2616},{"trials":2598,"activeCount":98},[],{"trials":2600,"activeCount":98},[],{"trials":2602,"activeCount":98},[],{"trials":2604,"activeCount":98},[2605],{"nctId":2606,"briefTitle":2607,"status":110,"phases":2608,"primaryCompletion":2609,"completion":2609,"start":2610,"enrollment":262,"conditions":2611,"interventions":2612},"NCT01595984","Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)",[88],"2018-08","2012-05-03",[2055],[2595,2613],"everolimus + mycophenolate mofetil",{"trials":2615,"activeCount":98},[],{"trials":2617,"activeCount":98},[],{"intervention":2613,"totalTrials":134,"cells":2619},{"EARLY_PHASE1":2620,"PHASE1":2622,"PHASE2":2624,"PHASE3":2626,"PHASE4":2632,"NA":2634},{"trials":2621,"activeCount":98},[],{"trials":2623,"activeCount":98},[],{"trials":2625,"activeCount":98},[],{"trials":2627,"activeCount":98},[2628],{"nctId":2606,"briefTitle":2607,"status":110,"phases":2629,"primaryCompletion":2609,"completion":2609,"start":2610,"enrollment":262,"conditions":2630,"interventions":2631},[88],[2055],[2595,2613],{"trials":2633,"activeCount":98},[],{"trials":2635,"activeCount":98},[],{"intervention":2637,"totalTrials":134,"cells":2638},"Corticoids plus N Acetyl Cysteine",{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2643,"PHASE3":2645,"PHASE4":2656,"NA":2658},{"trials":2640,"activeCount":98},[],{"trials":2642,"activeCount":98},[],{"trials":2644,"activeCount":98},[],{"trials":2646,"activeCount":98},[2647],{"nctId":2648,"briefTitle":2649,"status":221,"phases":2650,"primaryCompletion":2651,"completion":2439,"start":2050,"enrollment":2652,"conditions":2653,"interventions":2655},"NCT00863785","Treatment of Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone",[88],"2009-08",174,[2654],"Alcoholic Hepatitis",[2637],{"trials":2657,"activeCount":98},[],{"trials":2659,"activeCount":98},[],{"intervention":2661,"totalTrials":134,"cells":2662},"Sevelamer carbonate",{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2669,"PHASE4":2680,"NA":2682},{"trials":2664,"activeCount":98},[],{"trials":2666,"activeCount":98},[],{"trials":2668,"activeCount":98},[],{"trials":2670,"activeCount":98},[2671],{"nctId":2672,"briefTitle":2673,"status":221,"phases":2674,"primaryCompletion":2675,"completion":2675,"start":2676,"enrollment":236,"conditions":2677,"interventions":2679},"NCT01220843","FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease",[88],"2013-04","2010-10",[2678],"Chronic Renal Failure",[2661],{"trials":2681,"activeCount":98},[],{"trials":2683,"activeCount":98},[],{"intervention":2685,"totalTrials":134,"cells":2686},"Tetrabenazine",{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2693,"PHASE4":2706,"NA":2708},{"trials":2688,"activeCount":98},[],{"trials":2690,"activeCount":98},[],{"trials":2692,"activeCount":98},[],{"trials":2694,"activeCount":98},[2695],{"nctId":2696,"briefTitle":2697,"status":221,"phases":2698,"primaryCompletion":2699,"completion":2700,"start":2701,"enrollment":2702,"conditions":2703,"interventions":2705},"NCT01543321","Xenazine in Late Dyskinetic Syndrome With Neuroleptics",[88],"2017-05-18","2017-08","2012-05-14",54,[2704],"Tardive Dyskinesia",[2685],{"trials":2707,"activeCount":98},[],{"trials":2709,"activeCount":98},[],{"intervention":2711,"totalTrials":134,"cells":2712},"nicotinamide",{"EARLY_PHASE1":2713,"PHASE1":2715,"PHASE2":2717,"PHASE3":2719,"PHASE4":2734,"NA":2736},{"trials":2714,"activeCount":98},[],{"trials":2716,"activeCount":98},[],{"trials":2718,"activeCount":98},[],{"trials":2720,"activeCount":98},[2721],{"nctId":2722,"briefTitle":2723,"status":2724,"phases":2725,"primaryCompletion":2726,"completion":2726,"start":2727,"enrollment":2728,"conditions":2729,"interventions":2731},"NCT01011699","Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients","TERMINATED",[88],"2013-06","2010-01",176,[2678,2730],"Hemodialysis",[2711,2732,2733],"sevelamer","cinacalcet",{"trials":2735,"activeCount":98},[],{"trials":2737,"activeCount":98},[],{"intervention":2732,"totalTrials":134,"cells":2739},{"EARLY_PHASE1":2740,"PHASE1":2742,"PHASE2":2744,"PHASE3":2746,"PHASE4":2752,"NA":2754},{"trials":2741,"activeCount":98},[],{"trials":2743,"activeCount":98},[],{"trials":2745,"activeCount":98},[],{"trials":2747,"activeCount":98},[2748],{"nctId":2722,"briefTitle":2723,"status":2724,"phases":2749,"primaryCompletion":2726,"completion":2726,"start":2727,"enrollment":2728,"conditions":2750,"interventions":2751},[88],[2678,2730],[2711,2732,2733],{"trials":2753,"activeCount":98},[],{"trials":2755,"activeCount":98},[],{"intervention":2733,"totalTrials":134,"cells":2757},{"EARLY_PHASE1":2758,"PHASE1":2760,"PHASE2":2762,"PHASE3":2764,"PHASE4":2770,"NA":2772},{"trials":2759,"activeCount":98},[],{"trials":2761,"activeCount":98},[],{"trials":2763,"activeCount":98},[],{"trials":2765,"activeCount":98},[2766],{"nctId":2722,"briefTitle":2723,"status":2724,"phases":2767,"primaryCompletion":2726,"completion":2726,"start":2727,"enrollment":2728,"conditions":2768,"interventions":2769},[88],[2678,2730],[2711,2732,2733],{"trials":2771,"activeCount":98},[],{"trials":2773,"activeCount":98},[],{"intervention":2775,"totalTrials":134,"cells":2776},"Bupivacaine",{"EARLY_PHASE1":2777,"PHASE1":2779,"PHASE2":2781,"PHASE3":2783,"PHASE4":2796,"NA":2798},{"trials":2778,"activeCount":98},[],{"trials":2780,"activeCount":98},[],{"trials":2782,"activeCount":98},[],{"trials":2784,"activeCount":98},[2785],{"nctId":2786,"briefTitle":2787,"status":110,"phases":2788,"primaryCompletion":2789,"completion":2790,"start":2791,"enrollment":331,"conditions":2792,"interventions":2794},"NCT02801201","Impact of Analgesia on Success of External Version: Comparison of Spinal Anesthesia Versus Sedation",[88],"2019-10-30","2019-11-30","2016-05-31",[2793],"Breech Presentation",[2795,2775],"Midazolam",{"trials":2797,"activeCount":98},[],{"trials":2799,"activeCount":98},[],{"intervention":2801,"totalTrials":134,"cells":2802},"Sodium chloride administration",{"EARLY_PHASE1":2803,"PHASE1":2805,"PHASE2":2807,"PHASE3":2809,"PHASE4":2821,"NA":2823},{"trials":2804,"activeCount":98},[],{"trials":2806,"activeCount":98},[],{"trials":2808,"activeCount":98},[],{"trials":2810,"activeCount":98},[2811],{"nctId":2812,"briefTitle":2813,"status":1111,"phases":2814,"primaryCompletion":2815,"completion":2815,"start":2816,"enrollment":98,"conditions":2817,"interventions":2819},"NCT02819544","Evaluation of the Interest of the Instillation of Saline Intraperitoneally (INSI ) Versus Instillation of Naropin the Surgical Site Versus Lung Recruitment Maneuvers ( PVM ) in the Management of Pain After Laparoscopic Cholecystectomy in Ambulatory Care",[88],"2017-05-10","2016-09",[20,2818],"Pain",[2801,2820],"Ropivacaine administration",{"trials":2822,"activeCount":98},[],{"trials":2824,"activeCount":98},[],{"intervention":2820,"totalTrials":134,"cells":2826},{"EARLY_PHASE1":2827,"PHASE1":2829,"PHASE2":2831,"PHASE3":2833,"PHASE4":2839,"NA":2841},{"trials":2828,"activeCount":98},[],{"trials":2830,"activeCount":98},[],{"trials":2832,"activeCount":98},[],{"trials":2834,"activeCount":98},[2835],{"nctId":2812,"briefTitle":2813,"status":1111,"phases":2836,"primaryCompletion":2815,"completion":2815,"start":2816,"enrollment":98,"conditions":2837,"interventions":2838},[88],[20,2818],[2801,2820],{"trials":2840,"activeCount":98},[],{"trials":2842,"activeCount":98},[],{"intervention":2844,"totalTrials":94,"cells":2845},"Metformin",{"EARLY_PHASE1":2846,"PHASE1":2848,"PHASE2":2850,"PHASE3":2880,"PHASE4":2882,"NA":2884},{"trials":2847,"activeCount":98},[],{"trials":2849,"activeCount":98},[],{"trials":2851,"activeCount":98},[2852,2861,2872],{"nctId":2853,"briefTitle":2854,"status":221,"phases":2855,"primaryCompletion":2856,"completion":1183,"start":2006,"enrollment":2857,"conditions":2858,"interventions":2860},"NCT02710448","May Metformin be Used in Renal Failure?",[87],"2015-06",82,[2859],"Renal Disorder Associated With Type II Diabetes Mellitus",[2844],{"nctId":2862,"briefTitle":2863,"status":221,"phases":2864,"primaryCompletion":2865,"completion":2866,"start":2867,"enrollment":2868,"conditions":2869,"interventions":2871},"NCT02895750","Efficacity and Safety of Metformin XR in CKD Stage 1 to 3",[87],"2022-01-08","2022-10-10","2017-08-30",12,[2870],"Renal Insufficiency, Chronic",[2844],{"nctId":2873,"briefTitle":2874,"status":1111,"phases":2875,"primaryCompletion":2876,"completion":2876,"start":2877,"enrollment":98,"conditions":2878,"interventions":2879},"NCT02848508","Metformin in Moderate and Severe Renal Failure (CKD 3-4): A Follow-up Study",[87],"2017-06-07","2016-03-16",[2870],[2844],{"trials":2881,"activeCount":98},[],{"trials":2883,"activeCount":98},[],{"trials":2885,"activeCount":98},[],{"intervention":2887,"totalTrials":134,"cells":2888},"teicoplanin",{"EARLY_PHASE1":2889,"PHASE1":2891,"PHASE2":2893,"PHASE3":2904,"PHASE4":2906,"NA":2908},{"trials":2890,"activeCount":98},[],{"trials":2892,"activeCount":98},[],{"trials":2894,"activeCount":98},[2895],{"nctId":2896,"briefTitle":2897,"status":221,"phases":2898,"primaryCompletion":2856,"completion":2899,"start":2900,"enrollment":473,"conditions":2901,"interventions":2903},"NCT01815541","Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study",[87],"2015-07","2013-03",[2902],"Osteoarticular Infection",[2887],{"trials":2905,"activeCount":98},[],{"trials":2907,"activeCount":98},[],{"trials":2909,"activeCount":98},[],{"intervention":2911,"totalTrials":134,"cells":2912},"Timolol",{"EARLY_PHASE1":2913,"PHASE1":2915,"PHASE2":2917,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2914,"activeCount":98},[],{"trials":2916,"activeCount":98},[],{"trials":2918,"activeCount":98},[2919],{"nctId":2920,"briefTitle":2921,"status":221,"phases":2922,"primaryCompletion":2923,"completion":2924,"start":2925,"enrollment":1185,"conditions":2926,"interventions":2928},"NCT02422017","Topical Timolol Benefit in Venous Ulcers",[87],"2016-05","2018-01","2015-04",[2927],"Venous Leg Ulcers",[2911],{"trials":2930,"activeCount":98},[],{"trials":2932,"activeCount":98},[],{"trials":2934,"activeCount":98},[],{"intervention":2936,"totalTrials":134,"cells":2937},"Assess the absorption of oral amiodarone",{"EARLY_PHASE1":2938,"PHASE1":2940,"PHASE2":2942,"PHASE3":2953,"PHASE4":2955,"NA":2957},{"trials":2939,"activeCount":98},[],{"trials":2941,"activeCount":98},[],{"trials":2943,"activeCount":98},[2944],{"nctId":2945,"briefTitle":2946,"status":1111,"phases":2947,"primaryCompletion":2948,"completion":2948,"start":2949,"enrollment":98,"conditions":2950,"interventions":2952},"NCT03153072","Evaluation of the Pharmacokinetic Profile, Pharmacodynamic Effects, Acceptability and Tolerability of an Oral Amiodarone Solution of 15 mg \u002F mL in Children With Supra Ventricular Tachycardia",[87],"2017-03-01","2016-09-06",[2951],"Supraventricular Tachycardia",[2936],{"trials":2954,"activeCount":98},[],{"trials":2956,"activeCount":98},[],{"trials":2958,"activeCount":98},[],{"intervention":2960,"totalTrials":134,"cells":2961},"PAD-VCD",{"EARLY_PHASE1":2962,"PHASE1":2964,"PHASE2":2966,"PHASE3":2975,"PHASE4":2977,"NA":2979},{"trials":2963,"activeCount":98},[],{"trials":2965,"activeCount":98},[],{"trials":2967,"activeCount":98},[2968],{"nctId":2969,"briefTitle":2970,"status":221,"phases":2971,"primaryCompletion":2972,"completion":2816,"start":2727,"enrollment":1234,"conditions":2973,"interventions":2974},"NCT02858999","Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70",[87],"2016-07",[1094],[2960],{"trials":2976,"activeCount":98},[],{"trials":2978,"activeCount":98},[],{"trials":2980,"activeCount":98},[],{"intervention":2982,"totalTrials":134,"cells":2983},"Rituximab",{"EARLY_PHASE1":2984,"PHASE1":2986,"PHASE2":2988,"PHASE3":3000,"PHASE4":3002,"NA":3004},{"trials":2985,"activeCount":98},[],{"trials":2987,"activeCount":98},[],{"trials":2989,"activeCount":98},[2990],{"nctId":2991,"briefTitle":2992,"status":110,"phases":2993,"primaryCompletion":58,"completion":58,"start":2994,"enrollment":349,"conditions":2995,"interventions":2998},"NCT04113226","Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma",[87],"2021-07-26",[2996,2997,431],"Chemotherapy","Diffuse Large B-Cell Lymphoma (DLBCL), Nos",[2982,2999],"Lenalidomide 20 MG",{"trials":3001,"activeCount":98},[],{"trials":3003,"activeCount":98},[],{"trials":3005,"activeCount":98},[],{"intervention":2999,"totalTrials":134,"cells":3007},{"EARLY_PHASE1":3008,"PHASE1":3010,"PHASE2":3012,"PHASE3":3018,"PHASE4":3020,"NA":3022},{"trials":3009,"activeCount":98},[],{"trials":3011,"activeCount":98},[],{"trials":3013,"activeCount":98},[3014],{"nctId":2991,"briefTitle":2992,"status":110,"phases":3015,"primaryCompletion":58,"completion":58,"start":2994,"enrollment":349,"conditions":3016,"interventions":3017},[87],[2996,2997,431],[2982,2999],{"trials":3019,"activeCount":98},[],{"trials":3021,"activeCount":98},[],{"trials":3023,"activeCount":98},[],{"intervention":2795,"totalTrials":356,"cells":3025},{"EARLY_PHASE1":3026,"PHASE1":3028,"PHASE2":3030,"PHASE3":3032,"PHASE4":3038,"NA":3040},{"trials":3027,"activeCount":98},[],{"trials":3029,"activeCount":98},[],{"trials":3031,"activeCount":98},[],{"trials":3033,"activeCount":98},[3034],{"nctId":2786,"briefTitle":2787,"status":110,"phases":3035,"primaryCompletion":2789,"completion":2790,"start":2791,"enrollment":331,"conditions":3036,"interventions":3037},[88],[2793],[2795,2775],{"trials":3039,"activeCount":98},[],{"trials":3041,"activeCount":98},[3042],{"nctId":3043,"briefTitle":3044,"status":221,"phases":3045,"primaryCompletion":3046,"completion":3046,"start":3047,"enrollment":3048,"conditions":3049,"interventions":3050},"NCT03639428","Pharmacokinetic Evaluation of MDZ028",[],"2017-11-30","2011-06-23",37,[2795],[2795],{"intervention":1096,"totalTrials":134,"cells":3052},{"EARLY_PHASE1":3053,"PHASE1":3055,"PHASE2":3057,"PHASE3":3059,"PHASE4":3061,"NA":3063},{"trials":3054,"activeCount":98},[],{"trials":3056,"activeCount":98},[],{"trials":3058,"activeCount":98},[],{"trials":3060,"activeCount":98},[],{"trials":3062,"activeCount":98},[],{"trials":3064,"activeCount":98},[3065],{"nctId":1087,"briefTitle":1088,"status":221,"phases":3066,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":1092,"conditions":3067,"interventions":3068},[90],[1094],[1072,1096],{"intervention":3070,"totalTrials":134,"cells":3071},"blood alcohol concentration withdrawal",{"EARLY_PHASE1":3072,"PHASE1":3074,"PHASE2":3076,"PHASE3":3078,"PHASE4":3080,"NA":3082},{"trials":3073,"activeCount":98},[],{"trials":3075,"activeCount":98},[],{"trials":3077,"activeCount":98},[],{"trials":3079,"activeCount":98},[],{"trials":3081,"activeCount":98},[],{"trials":3083,"activeCount":98},[3084],{"nctId":3085,"briefTitle":3086,"status":221,"phases":3087,"primaryCompletion":3088,"completion":3088,"start":3089,"enrollment":3090,"conditions":3091,"interventions":3094},"NCT03998397","Self-estimates and Objective Blood Alcohol Concentration in Emergency Department",[90],"2020-06-18","2019-06-18",34,[3092,3093],"Alcohol Use Disorder","Blood Alcohol Content",[3070],{"intervention":3096,"totalTrials":134,"cells":3097},"neutrophil to lymphocyte ratio",{"EARLY_PHASE1":3098,"PHASE1":3100,"PHASE2":3102,"PHASE3":3104,"PHASE4":3106,"NA":3108},{"trials":3099,"activeCount":98},[],{"trials":3101,"activeCount":98},[],{"trials":3103,"activeCount":98},[],{"trials":3105,"activeCount":98},[],{"trials":3107,"activeCount":98},[],{"trials":3109,"activeCount":98},[3110],{"nctId":3111,"briefTitle":3112,"status":221,"phases":3113,"primaryCompletion":3114,"completion":3114,"start":3115,"enrollment":3116,"conditions":3117,"interventions":3119},"NCT02848534","The Value of the Neutrophil to Lymphocyte Ratio in the Diagnosis of Bacterial Infections",[],"2016-09-12","2016-02-06",479,[3118],"Bacterial Infections",[3096],{"intervention":3121,"totalTrials":134,"cells":3122},"Orcein staining",{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3127,"PHASE3":3129,"PHASE4":3131,"NA":3133},{"trials":3124,"activeCount":98},[],{"trials":3126,"activeCount":98},[],{"trials":3128,"activeCount":98},[],{"trials":3130,"activeCount":98},[],{"trials":3132,"activeCount":98},[],{"trials":3134,"activeCount":98},[3135],{"nctId":3136,"briefTitle":3137,"status":221,"phases":3138,"primaryCompletion":2925,"completion":2925,"start":3139,"enrollment":3140,"conditions":3141,"interventions":3143},"NCT02942862","Evaluation of New Histoprognostic Criteria in a Retrospective Study of Colon Cancers Operated at Amiens University Hospital",[],"2015-02",231,[3142],"Colonic Neoplasms",[3121],{"intervention":3145,"totalTrials":134,"cells":3146},"To study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker",{"EARLY_PHASE1":3147,"PHASE1":3149,"PHASE2":3151,"PHASE3":3153,"PHASE4":3155,"NA":3157},{"trials":3148,"activeCount":98},[],{"trials":3150,"activeCount":98},[],{"trials":3152,"activeCount":98},[],{"trials":3154,"activeCount":98},[],{"trials":3156,"activeCount":98},[],{"trials":3158,"activeCount":98},[3159],{"nctId":3160,"briefTitle":3161,"status":110,"phases":3162,"primaryCompletion":3163,"completion":3163,"start":3164,"enrollment":3165,"conditions":3166,"interventions":3170},"NCT03114826","Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients",[],"2019-10-05","2016-10-06",272,[3167,3168,3169,2054],"Polymorphism","VEGF","Renal Carcinoma",[3145],{"intervention":3172,"totalTrials":134,"cells":3173},"breast milk collection",{"EARLY_PHASE1":3174,"PHASE1":3176,"PHASE2":3178,"PHASE3":3180,"PHASE4":3182,"NA":3184},{"trials":3175,"activeCount":98},[],{"trials":3177,"activeCount":98},[],{"trials":3179,"activeCount":98},[],{"trials":3181,"activeCount":98},[],{"trials":3183,"activeCount":98},[],{"trials":3185,"activeCount":98},[3186],{"nctId":3187,"briefTitle":3188,"status":221,"phases":3189,"primaryCompletion":3190,"completion":3191,"start":3192,"enrollment":3193,"conditions":3194,"interventions":3202},"NCT03969459","Impact of Exposure to Persistent Organic Pollutants During Pregnancy on the Composition of Breast Milk and Consequences on the Newborn",[],"2021-05-28","2023-02-28","2019-05-28",88,[3195,3196,3197,3198,3199,3200,3201],"Pesticide","Breast Milk","Pollution; Exposure","Meconium","Stool","Microbiota","Newborn",[3172,3203,3204],"meconium collection","newborn feces collection",{"intervention":3203,"totalTrials":134,"cells":3206},{"EARLY_PHASE1":3207,"PHASE1":3209,"PHASE2":3211,"PHASE3":3213,"PHASE4":3215,"NA":3217},{"trials":3208,"activeCount":98},[],{"trials":3210,"activeCount":98},[],{"trials":3212,"activeCount":98},[],{"trials":3214,"activeCount":98},[],{"trials":3216,"activeCount":98},[],{"trials":3218,"activeCount":98},[3219],{"nctId":3187,"briefTitle":3188,"status":221,"phases":3220,"primaryCompletion":3190,"completion":3191,"start":3192,"enrollment":3193,"conditions":3221,"interventions":3222},[],[3195,3196,3197,3198,3199,3200,3201],[3172,3203,3204],{"intervention":3204,"totalTrials":134,"cells":3224},{"EARLY_PHASE1":3225,"PHASE1":3227,"PHASE2":3229,"PHASE3":3231,"PHASE4":3233,"NA":3235},{"trials":3226,"activeCount":98},[],{"trials":3228,"activeCount":98},[],{"trials":3230,"activeCount":98},[],{"trials":3232,"activeCount":98},[],{"trials":3234,"activeCount":98},[],{"trials":3236,"activeCount":98},[3237],{"nctId":3187,"briefTitle":3188,"status":221,"phases":3238,"primaryCompletion":3190,"completion":3191,"start":3192,"enrollment":3193,"conditions":3239,"interventions":3240},[],[3195,3196,3197,3198,3199,3200,3201],[3172,3203,3204],{"intervention":3242,"totalTrials":134,"cells":3243},"Sperm collection",{"EARLY_PHASE1":3244,"PHASE1":3246,"PHASE2":3248,"PHASE3":3250,"PHASE4":3252,"NA":3254},{"trials":3245,"activeCount":98},[],{"trials":3247,"activeCount":98},[],{"trials":3249,"activeCount":98},[],{"trials":3251,"activeCount":98},[],{"trials":3253,"activeCount":98},[],{"trials":3255,"activeCount":98},[3256],{"nctId":3257,"briefTitle":3258,"status":110,"phases":3259,"primaryCompletion":3260,"completion":3260,"start":3261,"enrollment":3262,"conditions":3263,"interventions":3264},"NCT02803658","Impact of Male Smoking on the Couple's Infertility",[90],"2018-09","2012-12-05",154,[1318],[3242],{"intervention":3266,"totalTrials":134,"cells":3267},"suprazygomatic maxillary nerve block",{"EARLY_PHASE1":3268,"PHASE1":3270,"PHASE2":3272,"PHASE3":3274,"PHASE4":3276,"NA":3278},{"trials":3269,"activeCount":98},[],{"trials":3271,"activeCount":98},[],{"trials":3273,"activeCount":98},[],{"trials":3275,"activeCount":98},[],{"trials":3277,"activeCount":98},[],{"trials":3279,"activeCount":98},[3280],{"nctId":3281,"briefTitle":3282,"status":1111,"phases":3283,"primaryCompletion":3284,"completion":3284,"start":3285,"enrollment":98,"conditions":3286,"interventions":3288},"NCT04023825","Analgesic Contribution of the Suprazygomatic Maxillary Nerve Block for Cleft Palate Surgery in Children",[90],"2022-07-01","2019-07-01",[3287,20],"Cleft Palate",[3266],{"intervention":3290,"totalTrials":134,"cells":3291},"plasma",{"EARLY_PHASE1":3292,"PHASE1":3294,"PHASE2":3296,"PHASE3":3298,"PHASE4":3300,"NA":3302},{"trials":3293,"activeCount":98},[],{"trials":3295,"activeCount":98},[],{"trials":3297,"activeCount":98},[],{"trials":3299,"activeCount":98},[],{"trials":3301,"activeCount":98},[],{"trials":3303,"activeCount":98},[3304],{"nctId":3305,"briefTitle":3306,"status":110,"phases":3307,"primaryCompletion":2609,"completion":2609,"start":3308,"enrollment":3309,"conditions":3310,"interventions":3312},"NCT02853682","Characterization of Endothelial Dysfunction as a Function of Hyperaemia of the Brachial Artery During Cardiac Surgery",[],"2016-01-20",28,[3311],"Capillary Leak Syndrome",[3290],{"intervention":3314,"totalTrials":134,"cells":3315},"Procalcitonin (PCT) as a diagnostic marker of bacterial infection",{"EARLY_PHASE1":3316,"PHASE1":3318,"PHASE2":3320,"PHASE3":3322,"PHASE4":3324,"NA":3326},{"trials":3317,"activeCount":98},[],{"trials":3319,"activeCount":98},[],{"trials":3321,"activeCount":98},[],{"trials":3323,"activeCount":98},[],{"trials":3325,"activeCount":98},[],{"trials":3327,"activeCount":98},[3328],{"nctId":3329,"briefTitle":3330,"status":221,"phases":3331,"primaryCompletion":3332,"completion":3332,"start":3333,"enrollment":3334,"conditions":3335,"interventions":3338},"NCT02898948","Procalcitonin (PCT) as a Diagnostic Marker of Bacterial Infection in the Patients Admitted for Fever and\u002For Inflammatory Syndrome to the Internal Medicine Department",[],"2016-10-18","2016-02-11",116,[3336,3337],"Systemic Inflammatory Response Syndrome","Fever",[3314],{"intervention":3340,"totalTrials":134,"cells":3341},"ICUS",{"EARLY_PHASE1":3342,"PHASE1":3344,"PHASE2":3346,"PHASE3":3348,"PHASE4":3350,"NA":3352},{"trials":3343,"activeCount":98},[],{"trials":3345,"activeCount":98},[],{"trials":3347,"activeCount":98},[],{"trials":3349,"activeCount":98},[],{"trials":3351,"activeCount":98},[],{"trials":3353,"activeCount":98},[3354],{"nctId":3355,"briefTitle":3356,"status":110,"phases":3357,"primaryCompletion":3358,"completion":3358,"start":2899,"enrollment":16,"conditions":3359,"interventions":3361},"NCT02804984","Identification of Molecular Defects in Idiopathic Cytopenia of Undetermined Significance",[],"2019-07",[3360],"Myelodysplastic Syndromes",[3340],{"intervention":3363,"totalTrials":134,"cells":3364},"thalidomide",{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3369,"PHASE3":3371,"PHASE4":3373,"NA":3375},{"trials":3366,"activeCount":98},[],{"trials":3368,"activeCount":98},[],{"trials":3370,"activeCount":98},[],{"trials":3372,"activeCount":98},[],{"trials":3374,"activeCount":98},[],{"trials":3376,"activeCount":98},[3377],{"nctId":3378,"briefTitle":3379,"status":221,"phases":3380,"primaryCompletion":3381,"completion":3382,"start":3383,"conditions":3384,"interventions":3387},"NCT00769587","Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis",[],"2011-05","2012-10","2007-06",[3385,3386],"Non Neoplastic Condition","Precancerous Condition",[3363],{"intervention":3389,"totalTrials":134,"cells":3390},"RANKL\u002FOPG ratio",{"EARLY_PHASE1":3391,"PHASE1":3393,"PHASE2":3395,"PHASE3":3397,"PHASE4":3399,"NA":3401},{"trials":3392,"activeCount":98},[],{"trials":3394,"activeCount":98},[],{"trials":3396,"activeCount":98},[],{"trials":3398,"activeCount":98},[],{"trials":3400,"activeCount":98},[],{"trials":3402,"activeCount":98},[3403],{"nctId":3404,"briefTitle":3405,"status":221,"phases":3406,"primaryCompletion":3407,"completion":3407,"start":3408,"enrollment":983,"conditions":3409,"interventions":3411},"NCT02799173","Determination of the RANKL\u002FOsteoprotegerin Ratio in Patients With Systemic Lupus Erythematosus. Role in Osteoporosis and Cardiovascular Calcification",[90],"2015-07-01","2011-04-15",[117,3410],"Lupus Erythematosus, Systemic",[3389],{"intervention":3413,"totalTrials":134,"cells":3414},"PCT dosage",{"EARLY_PHASE1":3415,"PHASE1":3417,"PHASE2":3419,"PHASE3":3421,"PHASE4":3423,"NA":3425},{"trials":3416,"activeCount":98},[],{"trials":3418,"activeCount":98},[],{"trials":3420,"activeCount":98},[],{"trials":3422,"activeCount":98},[],{"trials":3424,"activeCount":98},[],{"trials":3426,"activeCount":98},[3427],{"nctId":3428,"briefTitle":3429,"status":110,"phases":3430,"primaryCompletion":3431,"completion":3432,"start":3433,"enrollment":115,"conditions":3434,"interventions":3436},"NCT02821949","Evaluation of Serum Procalcitonin Rate in Patients With Stage IV Non-small Cell Lung Cancer in First Line Chemotherapy",[],"2017-06","2017-07","2014-12",[3435],"Non Small Cells Lung Cancer",[3413],{"intervention":3438,"totalTrials":134,"cells":3439},"Adverse events detection",{"EARLY_PHASE1":3440,"PHASE1":3442,"PHASE2":3444,"PHASE3":3446,"PHASE4":3448,"NA":3450},{"trials":3441,"activeCount":98},[],{"trials":3443,"activeCount":98},[],{"trials":3445,"activeCount":98},[],{"trials":3447,"activeCount":98},[],{"trials":3449,"activeCount":98},[],{"trials":3451,"activeCount":98},[3452],{"nctId":3453,"briefTitle":3454,"status":221,"phases":3455,"primaryCompletion":3456,"completion":3456,"start":3457,"enrollment":1045,"conditions":3458,"interventions":3460},"NCT03599999","Study of Adverse Effects Occuring in Patients Receiving an Antibiotic Treatment With Temocillin",[],"2017-12-29","2017-03-24",[3459],"Bacterial Infection With One or More Extended Spectrum Betalactamases Remaining Susceptible to Temocillin",[3438],{"intervention":3462,"totalTrials":134,"cells":3463},"MEMOPTIC",{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3468,"PHASE3":3470,"PHASE4":3472,"NA":3474},{"trials":3465,"activeCount":98},[],{"trials":3467,"activeCount":98},[],{"trials":3469,"activeCount":98},[],{"trials":3471,"activeCount":98},[],{"trials":3473,"activeCount":98},[],{"trials":3475,"activeCount":98},[3476],{"nctId":3477,"briefTitle":3478,"status":110,"phases":3479,"primaryCompletion":3480,"completion":3480,"start":3481,"enrollment":249,"conditions":3482,"interventions":3485},"NCT04499157","Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma",[90],"2023-08","2020-08-01",[3483,3484],"Open-angle Glaucoma","Visual Field",[3462,3486],"usual treatment of glaucoma",{"intervention":3486,"totalTrials":134,"cells":3488},{"EARLY_PHASE1":3489,"PHASE1":3491,"PHASE2":3493,"PHASE3":3495,"PHASE4":3497,"NA":3499},{"trials":3490,"activeCount":98},[],{"trials":3492,"activeCount":98},[],{"trials":3494,"activeCount":98},[],{"trials":3496,"activeCount":98},[],{"trials":3498,"activeCount":98},[],{"trials":3500,"activeCount":98},[3501],{"nctId":3477,"briefTitle":3478,"status":110,"phases":3502,"primaryCompletion":3480,"completion":3480,"start":3481,"enrollment":249,"conditions":3503,"interventions":3504},[90],[3483,3484],[3462,3486],{"intervention":3506,"totalTrials":134,"cells":3507},"antibiotic concentration in pleural fluid",{"EARLY_PHASE1":3508,"PHASE1":3510,"PHASE2":3512,"PHASE3":3514,"PHASE4":3516,"NA":3518},{"trials":3509,"activeCount":98},[],{"trials":3511,"activeCount":98},[],{"trials":3513,"activeCount":98},[],{"trials":3515,"activeCount":98},[],{"trials":3517,"activeCount":98},[],{"trials":3519,"activeCount":98},[3520],{"nctId":3521,"briefTitle":3522,"status":221,"phases":3523,"primaryCompletion":3524,"completion":3524,"start":3525,"enrollment":2366,"conditions":3526,"interventions":3532},"NCT04350502","Pharmacokinetics and Pleural Fluid Penetration of Amoxicillin and Clavulanic Acid in Patients With Pleural Infections",[90],"2025-12-01","2019-07-18",[3527,3528,3529,3530,3531],"Pleural Infection","Empyema","Community-acquired Pneumonia","Pharmacokinetic","Amoxicillin",[3506,3533],"Amoxicillin + clavulanic acid",{"intervention":3533,"totalTrials":134,"cells":3535},{"EARLY_PHASE1":3536,"PHASE1":3538,"PHASE2":3540,"PHASE3":3542,"PHASE4":3544,"NA":3546},{"trials":3537,"activeCount":98},[],{"trials":3539,"activeCount":98},[],{"trials":3541,"activeCount":98},[],{"trials":3543,"activeCount":98},[],{"trials":3545,"activeCount":98},[],{"trials":3547,"activeCount":98},[3548],{"nctId":3521,"briefTitle":3522,"status":221,"phases":3549,"primaryCompletion":3524,"completion":3524,"start":3525,"enrollment":2366,"conditions":3550,"interventions":3551},[90],[3527,3528,3529,3530,3531],[3506,3533],{"intervention":3553,"totalTrials":134,"cells":3554},"serodiagnosis",{"EARLY_PHASE1":3555,"PHASE1":3557,"PHASE2":3559,"PHASE3":3561,"PHASE4":3563,"NA":3565},{"trials":3556,"activeCount":98},[],{"trials":3558,"activeCount":98},[],{"trials":3560,"activeCount":98},[],{"trials":3562,"activeCount":98},[],{"trials":3564,"activeCount":98},[],{"trials":3566,"activeCount":98},[3567],{"nctId":3568,"briefTitle":3569,"status":221,"phases":3570,"primaryCompletion":3571,"completion":3571,"start":3572,"enrollment":3573,"conditions":3574,"interventions":3576},"NCT02798965","Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study",[90],"2014-05","2010-12",52,[3575],"Graves Disease",[3553],{"intervention":3578,"totalTrials":134,"cells":3579},"anticoagulation by unfractionated heparin",{"EARLY_PHASE1":3580,"PHASE1":3582,"PHASE2":3584,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3581,"activeCount":98},[],{"trials":3583,"activeCount":98},[],{"trials":3585,"activeCount":98},[],{"trials":3587,"activeCount":98},[],{"trials":3589,"activeCount":98},[],{"trials":3591,"activeCount":98},[3592],{"nctId":3593,"briefTitle":3594,"status":221,"phases":3595,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":3598,"conditions":3599,"interventions":3601},"NCT02848612","Evaluation of the Amiens University Hospital Neuroradiology Anticoagulation Protocol",[],"2016-07-15","2015-11-20",459,[3600],"Aneurysm",[3578],{"intervention":3603,"totalTrials":134,"cells":3604},"Octreotide",{"EARLY_PHASE1":3605,"PHASE1":3607,"PHASE2":3609,"PHASE3":3611,"PHASE4":3613,"NA":3615},{"trials":3606,"activeCount":98},[],{"trials":3608,"activeCount":98},[],{"trials":3610,"activeCount":98},[],{"trials":3612,"activeCount":98},[],{"trials":3614,"activeCount":98},[],{"trials":3616,"activeCount":98},[3617],{"nctId":3618,"briefTitle":3619,"status":1111,"phases":3620,"primaryCompletion":3621,"completion":3621,"start":3622,"enrollment":98,"conditions":3623,"interventions":3626},"NCT03891849","Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock",[90],"2023-05","2021-09-01",[3624,3625],"Haemorrhagic Shock","Variceal Hemorrhage",[3603]]